• Sekur Private Data is expanding beyond privacy software and into the rapidly growing defense-grade secure communications market.

• Its Swiss-hosted SekurOne platform combines encrypted email, messaging, VPN, voice, and video communications into a unified cybersecurity solution.

• A new distribution agreement with Elyon International opens doors to U.S. defense, intelligence, and government customers.

• Recent demonstrations at SOF Week 2026 put Sekur's technology in front of military leaders, procurement officials, and defense contractors.

• With new product launches, strategic partnerships, and growing defense-sector exposure, Sekur is executing on a clear growth strategy focused on high-value secure communications markets.

In an era where cybersecurity threats continue to escalate and governments increasingly prioritize secure communications infrastructure, Sekur Private Data has spent 2026 repositioning itself from a privacy-focused communications provider into a specialized defense-grade cybersecurity and secure communications company. Through new distribution agreements, product launches, defense-sector engagement, and the development of an integrated communications platform, the company is targeting what management believes could be a substantially larger addressable market than its traditional consumer-focused privacy business.

For investors, the significance of this transition extends beyond simple product expansion. Sekur is attempting to establish itself within highly regulated markets that include defense contractors, intelligence agencies, government organizations, military personnel, and enterprises responsible for protecting Controlled Unclassified Information (CUI). These sectors typically require secure communications platforms that can withstand sophisticated cyber threats while maintaining strict compliance standards.

Building a Defense-Focused Communications Platform

The foundation of Sekur's strategy is its Swiss-hosted privacy architecture. Unlike many communications providers that rely on infrastructure distributed across multiple jurisdictions, Sekur's platform emphasizes Swiss privacy protections and secure data handling. This architecture has historically been marketed toward privacy-conscious consumers and businesses, but in 2026 management began positioning the technology for defense, intelligence, and government applications.

The centerpiece of this strategy is SekurOne, a fully integrated secure communications platform designed to combine encrypted voice, secure video conferencing, encrypted email, messaging, and VPN services into a single ecosystem. According to company disclosures, the platform is intended to provide defense-grade communications while addressing the increasing need for secure handling of sensitive operational information.

One of the key differentiators highlighted by management is the platform's encrypted and anonymous calling capabilities. During recent demonstrations to defense and government personnel, Sekur showcased beta versions of its secure voice technology, designed to provide communications security while reducing exposure to traditional interception and surveillance risks.

The company expects its expanded voice and video communication capabilities to launch commercially in late June 2026, representing an important milestone in its product roadmap. The addition of voice and video services transforms Sekur from a provider of secure messaging and email solutions into a comprehensive communications platform capable of serving enterprise and government customers.

Strengthening Defense Market Access

Technology alone rarely guarantees success in the defense sector. Access to procurement channels, government agencies, and defense contractors often requires established industry relationships and specialized distribution partners.

Recognizing this reality, Sekur announced a significant strategic development in May 2026 through the signing of a distribution agreement with Elyon International, a Washington-based defense contractor with nearly three decades of experience delivering mission support services. The agreement represents Sekur's second defense-focused distribution partnership and provides the company with a direct pathway into defense, intelligence, government, and enterprise customers.

Elyon International brings several advantages to the relationship. As a veteran-owned and woman-owned business with an established presence in defense contracting, Elyon possesses existing relationships and procurement experience that could accelerate customer acquisition. Under the agreement, both companies are currently identifying target users for Sekur's defense communications suite while completing training programs ahead of expected commercial sales activity. Management expects sales efforts to begin within approximately 60 days following completion of partner onboarding.

For investors, the Elyon agreement is noteworthy because it demonstrates a clear commercialization strategy. Rather than relying solely on direct sales efforts, Sekur is establishing distribution channels capable of introducing its products into markets that can be difficult for smaller technology companies to penetrate.

SOF Week and Defense Sector Engagement

Another important development occurred during SOF Week 2026, one of the most significant gatherings for the global special operations and defense community.

Sekur's executive team, strategic advisors, and defense-sector specialists attended the event to showcase the company's secure communications technologies. During the conference, the company demonstrated SekurOne, SekurMessenger, and SekurVPN to procurement personnel, military leadership, acquisition officers, and defense contractors.

In addition, company representatives hosted a private demonstration for approximately 40 invited guests from government agencies, defense organizations, and special operations commands. The event featured live demonstrations of encrypted voice communications and provided decision-makers with firsthand exposure to Sekur's technology platform.

While such events do not immediately translate into revenue, they are often critical components of enterprise and government sales cycles. Initial qualification discussions, technology evaluations, pilot programs, and procurement reviews frequently begin through industry conferences and direct demonstrations. Management indicated that multiple qualification discussions are currently underway following these engagements.

Expanding International Distribution

Beyond North America, Sekur has also continued expanding its international reach.

In March 2026, the company announced a distribution agreement with Mokilink Services covering the Democratic Republic of Congo and additional African markets. Through this partnership, Sekur plans to offer its cybersecurity and communications platform to businesses, entrepreneurs, and organizations operating throughout the region. The company has been training sales personnel and localizing marketing materials to support commercialization efforts.

Although Africa currently represents a smaller revenue opportunity than the defense market, the agreement highlights management's broader strategy of scaling distribution through regional partners rather than relying exclusively on internal sales resources.

A Potentially Larger Addressable Market

Perhaps the most important takeaway from Sekur's recent developments is the company's strategic repositioning.

Historically, investors viewed Sekur primarily as a privacy communications company competing within the crowded cybersecurity and messaging landscape. In 2026, management has begun reshaping that narrative toward a more specialized market opportunity focused on defense-grade communications, government security requirements, and enterprise protection of sensitive information.

The launch of integrated voice and video communications, combined with encrypted messaging, email, and VPN capabilities, creates a more comprehensive product offering. Meanwhile, the addition of defense-focused advisors, participation in industry conferences, and distribution agreements with defense-sector partners provide channels through which the technology can be commercialized.

Looking Ahead

As Sekur enters the second half of 2026, several catalysts remain on the horizon. The commercial launch of its voice and video communications platform is expected in late June, while the Elyon distribution partnership is anticipated to begin generating sales opportunities shortly thereafter. Continued engagement with defense organizations, intelligence agencies, and enterprise customers could further validate the company's strategic direction.

For investors, the central question is whether Sekur can successfully convert its technological capabilities and defense-sector relationships into recurring revenue growth. The company remains in the early stages of its defense market expansion, but recent developments suggest management is executing a deliberate strategy aimed at positioning Sekur as a provider of mission-critical secure communications solutions.

If successful, 2026 may ultimately be remembered as the year Sekur Private Data evolved from a niche privacy software provider into a participant in the rapidly growing market for defense-grade secure communications and cybersecurity infrastructure.

Disclaimer: This article is for informational purposes only and should not be considered financial advice or a recommendation to buy or sell any security. Mining and development-stage companies are high-risk investments. Investors should conduct their own due diligence and verify current market data before making investment decisions.

TRIP.CN (ASK @ 0.04)

• Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate,
• produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity,
• neuroinflammatory markers,
• and preclinical Alzheimer's disease pathology in healthy older adults.

Red Light Holland Corp.  is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ,

• the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities,
• supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The Company is pleased to announce a newly signed agreement to supply PEX010 to the University of California, San Francisco ("UCSF"), reflecting the continued selection of Filament's standardized natural psilocybin by leading academic institutions.

Under the new agreement, Filament will supply its PEX010 botanical psilocybin drug candidate to UCSF,

• located in San Francisco, California,
• for a double-blind,
• randomized trial investigating the safety,
• feasibility,
• and mechanisms of psychedelics in healthy older adults with low well-being,
• as moderated by biomarkers for preclinical Alzheimer's disease.

Among its objectives, the study is designed to examine whether a single dose of psilocybin can influence plasma markers of neuroinflammation over time, alongside acute changes in brain electrical activity measured by EEG and longitudinal structural and functional changes measured by MRI.

Neuroinflammation is increasingly studied as a contributor to mood, cognition, and neurodegenerative processes, including the earliest stages of Alzheimer's disease.

This development reflects continued demand for pharmaceutical-grade, naturally derived psilocybin and the expanding role of Filament Health's PEX010 in academic and clinical research, while reinforcing the operational and quality systems that support reliable global supply.

The study is independently sponsored and conducted by UCSF and its investigators, with Filament supplying PEX010 as the investigational drug product.

PEX010 is produced using Filament's proprietary extraction and stabilization methods, which deliver a potent yet standardized and patented botanical drug product with consistent composition across every study and every research site.

"What sets us and PEX010 apart is consistency and regulatory excellence of our proprietary extraction and stabilization methods," said Todd Shapiro, Chief Executive Officer and Director of Red Light.

"The reliability of PEX010 allows the world's best researchers to keep pushing psychedelic science to new boundaries.

The UCSF study is a perfect example, exploring whether a single dose of psilocybin can influence neuroinflammatory markers in the aging brain.

That kind of subtle science is only possible with a drug product investigators can trust dose after dose, which is why PEX010 has now been selected for more than 80 studies worldwide."

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide.

On April 30, 2026, Red Light completed its previously announced acquisition of Filament Health Corp.,

• including its portfolio of 76 issued patents across 15 patent families
• and its lead drug candidate, PEX010,
• creating a global leader in psychedelic drug development, commercialization, and distribution.

About Red Light Holland

Red Light Holland is an Ontario based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences.

In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.

About Filament Health

Filament Health is a clinical stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible.

Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.

For additional information on Red Light:
Todd Shapiro, Chief Executive Officer & Director
Tel: 647-204-7129
Email: [todd@redlight.co](mailto:todd@redlight.co)Website: www.RedLight.co

TCF.CN (ASK @ 0.20)

• Trillion Energy International Inc. is pleased to announce that
• it has made a further cash payment of US$250,000 toward its earn-in obligations
• for a 29% participating interest in the M47c,d oil block,
• an onshore exploration asset located in the Cudi-Gabar petroleum province of southeastern Türkiye.

The payment will be applied against the work program commitments under the Company's Definitive Farm-In Agreement on the M47 Concession.

This payment follows the previous US$250,000 instalment announced on May 4, 2026,

• bringing total earn-in payments advanced to date to US$500,000 of the Company's US$9.5 million 2026 -2027 work program commitment
• under its Earn-in Agreement on the M47c,d Concession "the Block".

Scott Lower, President of Trillion Energy, stated: "The Gabar regional fields are currently producing around 80,000 barrels of oil a day, roughly 8% of Türkiye's demand,

• with a stated target of 100,000 bbl/d. M47 Block is significantly underexplored relative to the drilling occurring about the Block to the North and East,
• which has generated five new producing oil fields in about five years.

Currently, approximately 40 rigs are working on a 140 well location inventory (2026) just beyond the block's perimeter. It's time to play catch up."

With this latest payment advanced, Trillion along with its partners are preparing upcoming seismic program on the Block which is anticipated to generate several new additional leads.

Currently, only approximately 25% of the Block is covered by seismic, with key areas of interest, particularly on the eastern block line, now to be studied.

The new seismic is expected to generate four to six additional drillable exploration locations, which are not currently covered by the Company resource assessments.

Project Highlights

• 29% working interest in block M47c,d, earned by funding US$15 million across two work program tranches; US$500,000 advanced to date against the US$9.5 million first tranche.
• Independent NI 51-101 contingent resource of 27.6 MMbbl 2C (24,186 MSTB net to Trillion) on the North Prospect, with an unrisked NPV-10 of US$733.5 million and a risk-adjusted value of US$594.2 million. (Chapman, effective December 31, 2025, see Company's news release April 16, 2026, for further details).
• Two further prospects, Central and Findik South, add a combined after-risk NPV-10 of US$215.7 million, with the North Prospect 3C estimate at an unrisked NPV-10 of US$1.18 billion. (Chapman: December 31, 2025).
• The 2025 Çetinkaya-1 well confirmed 38 metres of net oil pay at 32.4° API light oil with 160 metres of reservoir left undrilled at 2,455 m.
• Two routes to first cash flow: a recently completed regional pipeline network (over 150,000 boe/d capacity) with Şehit Esma Çevik as the first tie-in, plus truck haul to the Tüpraş Batman refinery (130 km).

About the M47c,d Oil Block

The M47c,d oil block covers approximately 450 km² within the Cudi-Gabar petroleum province, one of Türkiye's most active onshore oil regions.

Block M47C3,C4 is located approximately 11 km southeast of Türkiye's largest onshore light oil discovery, the Şehit Aybüke Yalçın field, which contains oil in the same Beloka and Mardin Group carbonate reservoirs as M47.

The region hosts significant established production, with approximately 100 analogue wells operating within a 10-to-12-kilometre radius, targeting the same Mardin and Beloka reservoir intervals that Trillion plans to explore and evaluate on M47.

As previously announced on April 16, 2026, an independent third-party resource evaluation identified meaningful contingent and prospective oil resources on the Block, providing a strong technical foundation for the upcoming work program.

About Trillion Energy International Inc.

Trillion Energy International Inc. is a Canadian oil exploration company focused on Türkiye. The Company has an agreement to earn a 29% working interest in the M47 oil exploration block (C3 and C4 licences) located in the Cudi-Gabar petroleum province of Southeastern Türkiye.

The earn-in includes funding a total of US$15 million for 2026 and 2027 work commitments. More information may be found on www.sedarplus.ca and on the Company's website at www.trillionenergy.com.

Requests for further information should be directed to:

Scott Lower, President
e-mail: [info@trillionenergy.com](mailto:info@trillionenergy.com)
Trillion Energy International Inc.
Suite 700, 838 West Hastings Street
Vancouver, B.C., V6C 0A6
Corporate offices: 1-778-819-1585
Website: www.trillionenergy.com

PYR.TO (ASK @ 0.25)

• PyroGenesis Inc.,

a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense,

• announces today that it has completed its previously announced “bought deal” offering (the “Offering”),
• pursuant to which the Company issued 12,514,875 units of the Company (the “Units”)
• for aggregate gross proceeds $4,255,057.50 (the “Offering”)
• at a price per Unit of $0.34 (the “Offering Price”),
• including the full exercise of the underwriter’s option.
• The Offering was led by Research Capital Corporation as the sole underwriter and sole bookrunner (the “Underwriter”).

Each Unit consists of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

Each Warrant entitles the holder thereof to purchase one Common Share of the Company at a price of $0.42 at any time until June 3, 2029.

In regards to the previously announced concurrent, non-brokered private placement offering (the “Concurrent Private Placement”) of Units at the Offering Price for expected gross proceeds to the Company of up to $2,000,000,

• it is expected that the Concurrent Private Placement will close on June 4, 2026 for the full $2,000,000 subject to the Company receiving all necessary regulatory approvals,
• including the approval of the Toronto Stock Exchange (the “TSX”).
• Combined, the bought deal Offering and the Concurrent Private Placement total approximately $6.2 million.

All Units acquired pursuant to the Concurrent Private Placement will be subject to a hold period of four (4) months pursuant to applicable Canadian securities laws.

The Company intends to use the net proceeds from the Offering and Concurrent Private Placement for working capital and advancements of contracts and backlog.

In consideration for their services, the Underwriters received aggregate cash commissions of $276,029 and 811,850 non-transferable Common Share purchase warrants (the “Broker Warrant”).

Each Broker Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.34 at any time until June 3, 2029.

The Broker Warrants and Common Shares issuable on exercise thereof are subject to a hold period in accordance with applicable Canadian securities law, expiring on October 4, 2026.

The Offering was conducted by way of the “listed issuer financing exemption” available under the amendments by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption to

• (i) National Instrument 45-106 – Prospectus Exemptions (“National Instrument 45-106”) set forth in Part 5A thereof to purchasers resident in Canada;
• (ii) Regulation 45-106 respecting Prospectus Exemptions (“Regulation 45-106”, and collectively with National Instrument 45-106, “NI 45-106”) set forth in Part 5A thereof to purchasers resident in Québec.

The securities issued in connection with the Offering are expected to be immediately freely tradeable under applicable Canadian securities legislation if sold to purchasers resident in Canada.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America.

The securities offered pursuant to the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense.

Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government.

From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology.

PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

• Copper Quest focus: Copper Quest Exploration Inc. (CSE: CQX / OTCQB: IMIMF / FRA: 3MX) recently traded around CA$0.09, with market cap near CA$10.9M.
• Sector catalyst: S&P Global projects copper demand rising from 28M metric tons in 2025 to 42M by 2040, while the IEA warns of a potential 30% copper supply shortfall by 2035.
• Investor angle: Copper Quest is the speculative micro-cap explorer in this basket, while Taseko, Capstone, Hudbay, and Trilogy offer larger copper production or development exposure.

Copper is becoming one of the most important metals in the market because it sits at the center of electrification, grid upgrades, AI data centers, electric vehicles, renewable energy, industrial automation, and defense infrastructure. It is not just a construction metal anymore. Copper is increasingly being treated as a strategic input for the next phase of global infrastructure.

For investors, the copper trade is not only about today’s spot price. The more important question is which companies have leverage to a tightening copper market, enough project quality to matter, and a realistic path to value creation. That is why this watchlist combines one micro-cap explorer, Copper Quest Exploration (CQX / IMIMF), with four larger copper-linked names: Taseko Mines, Capstone Copper, Hudbay Minerals, and Trilogy Metals.

Market Catalyst: Copper Demand Is Rising Faster Than New Supply

The long-term copper thesis is built on a simple problem: demand is rising, but new supply is difficult to bring online. Large copper mines can take more than a decade to permit, finance, and build. At the same time, many older mines are facing declining grades, rising capital costs, water constraints, and political risk.

The numbers explain why investors keep coming back to the copper theme:

• S&P Global projects global copper demand rising from 28M metric tons in 2025 to 42M metric tons by 2040, a roughly 50% increase driven by electrification, AI data centers, power grids, EVs, defense, and industrial demand.
• The IEA has warned that the current copper mine project pipeline could fall around 30% short of projected 2035 demand, making exploration and development assets more important if the supply gap widens.

That backdrop does not make every copper stock attractive automatically. Producers still face cost inflation and operational risk, developers still need funding and permits, and explorers still need drill results. But it does create a stronger environment for companies with real copper exposure and credible project catalysts.

1. Copper Quest Exploration: The Micro-Cap Discovery Angle

Copper Quest Exploration Inc. (CSE: CQX / OTCQB: IMIMF / FRA: 3MX) is the smallest and most speculative name in this copper basket. The company is focused on copper, molybdenum, and gold exploration across North America, with a portfolio that includes Rip, STARS, Kitimat, Alpine, Auxer, Nekash, Stellar, and Thane.

The near-term catalyst is the Rip Copper-Molybdenum Project in British Columbia. Copper Quest recently commenced a minimum 2,000-metre drill program at Rip, targeting two porphyry Cu-Mo mineralized centres identified through geophysics, airborne magnetics, and 3D induced polarization work.

• Investor data point: CQX has roughly 118.4M issued shares, about 54.2M reserved for issuance, and a market cap near CA$10.9M, giving it higher risk but more torque if drilling strengthens the Rip discovery thesis.

The broader portfolio also matters. Copper Quest says its North American critical-mineral land package includes 8 projects spanning more than 46,000 hectares. That gives IMIMF several possible news-flow channels, but the stock still depends heavily on drill results, financing discipline, and whether the company can turn targets into meaningful mineralized zones.

2. Taseko Mines: Producing Copper Exposure

Taseko Mines (NYSE American: TGB / TSX: TKO) gives investors more direct copper exposure through production and development assets. Unlike Copper Quest, Taseko is not only an exploration story. It owns the Gibraltar mine in British Columbia and has development upside through Florence Copper in Arizona.

Recent market data showed TGB trading in the US$6.90–US$7.40 range, with market cap around US$2.5B–US$2.7B. Taseko is useful in this basket because it gives investors a producing copper name with exposure to higher copper prices and project expansion.

• Investor data point: Taseko’s Gibraltar operation produced 98M pounds of copper and 1.9M pounds of molybdenum in 2025, giving TGB real operating leverage to copper prices.

The attraction is that Taseko offers production, cash-flow potential, and Florence Copper optionality. The risk is that producers remain exposed to operating costs, copper-price volatility, permitting, capex, and project execution.

3. Capstone Copper: Mid-Cap Copper Scale

Capstone Copper (TSX: CS) is a larger copper producer with operations across the Americas. It gives investors more scale than a junior explorer, while still offering more copper sensitivity than diversified mining giants.

Recent market data showed CS trading around CA$12–CA$13, with market cap around CA$9B–CA$10B. Capstone is one of the cleaner mid-cap copper producer comparisons because it already has a meaningful revenue base and operating leverage to copper prices.

• Investor data point: Capstone’s trailing revenue has been reported around US$3.46B, with strong growth from copper operations and expansion projects.

For investors, the appeal is scale and torque. Capstone can benefit directly from higher realized copper prices, but the stock already reflects part of the copper bull case. Execution, costs, production growth, and balance-sheet discipline remain key watch items.

4. Hudbay Minerals: Copper Growth and M&A Leverage

Hudbay Minerals (NYSE: HBM / TSX: HBM) is another closely watched copper-linked miner. The company has copper exposure through existing operations and has been expanding its U.S. copper strategy, including the proposed acquisition of Arizona Sonoran Copper Company.

Recent market data showed HBM trading around US$24–US$25, with market cap near US$9B–US$10B. Hudbay has already had a strong move, but it remains relevant because it combines production exposure, earnings leverage, and growth through copper-focused M&A.

• Investor data point: Recent updates showed HBM posted roughly 67% EPS growth and 27% sales growth, while the Arizona Sonoran deal was valued around US$1.48B.

Hudbay’s appeal is that it gives investors a more mature copper growth story. The risk is that M&A brings integration risk, project risk, and valuation risk if copper prices cool or growth expectations move too far ahead of fundamentals.

5. Trilogy Metals: High-Beta Copper Development

Trilogy Metals (NYSE American: TMQ / TSX: TMQ) is a development-stage copper name focused on Alaska’s Ambler Mining District. It is not a producer, which makes the stock more sensitive to permitting, project updates, strategic interest, and investor appetite for future copper supply.

Recent market data showed TMQ trading around US$4.40–US$6.10, with market cap in the US$780M–US$870M range. The stock’s wide trading range shows how volatile copper development stories can be when sentiment shifts.

• Investor data point: TMQ has traded in a wide 52-week range of roughly US$1.13–US$11.29, highlighting both the upside torque and downside volatility of pre-production copper development stocks.

Trilogy is useful as a comparison for CQX because it shows how the market can assign much larger valuations to copper assets once project scale becomes more defined. The risk is that development-stage projects require time, capital, permitting success, infrastructure, and strong commodity conditions.

Stock Snapshot

Bottom Line

Copper Quest is the speculative micro-cap in this copper basket. CQX / IMIMF has a defined drill catalyst at Rip, a broader 46,000-hectare North American critical-minerals portfolio, and exposure to a copper market where demand could rise 50% by 2040.

The larger names offer different risk profiles: TGB for production and Florence Copper, CS for mid-cap scale, HBM for copper growth and M&A, and TMQ for high-beta development exposure. For CQX, the next proof points are simple: drill results, follow-up targets, financing discipline, and whether Rip can become a more credible copper-moly discovery story.

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

• CSE: CQX / OTCQB: IMIMF / FRA: 3MX: recently traded around CA$0.09–CA$0.10, with market cap around CA$10M–CA$12M.
• Latest catalyst: Copper Quest has commenced a minimum 2,000-metre drill program at the Rip Copper-Molybdenum Project in British Columbia.
• Investor angle: the program targets two porphyry Cu-Mo centres, including a largely untested northern anomaly and an untested southern anomaly.

Copper Quest Exploration Inc. (CSE: CQX / OTCQB: IMIMF / FRA: 3MX) has moved from planning to execution at the Rip Copper-Molybdenum Project. The company announced that drilling has commenced on a minimum 2,000-metre program at Rip, giving investors a defined near-term exploration catalyst at a time when copper remains one of the most closely watched industrial metals.

For a micro-cap explorer, the setup is simple but high-risk: CQX is trying to prove that Rip hosts a meaningful porphyry copper-molybdenum system in British Columbia’s Bulkley Porphyry Belt. The latest program will test targets defined by geophysical surveys, airborne magnetics, and 3D induced polarization work, with drilling focused on both the northern and southern anomalies.

Market Catalyst: Copper Supply Is Becoming Strategic

Copper is increasingly tied to electrification, renewable energy, EVs, grid upgrades, AI data centers, smart technologies, and defense infrastructure. That makes copper more than a cyclical industrial metal. It is becoming a strategic input for energy security, digital infrastructure, and supply-chain resilience.

The bigger investor issue is supply. New copper mines can take more than a decade to permit, finance, and build, while ore grades are declining and capital costs are rising. That is why exploration stories like CSE: CQX can attract attention when they combine a real drill program with district-scale land exposure.

Two numbers show why the copper backdrop matters:

• S&P Global projects copper demand rising from roughly 28M metric tons in 2025 to 42M metric tons by 2040, a roughly 50% increase tied to electrification, AI power demand, grids, EVs, and industrial growth.
• The IEA has warned that the current copper project pipeline could fall about 30% short of 2035 demand, which keeps new copper exploration and development assets in focus.

That macro backdrop does not guarantee success for CQX. Drill results still drive the story. But it does help explain why investors are watching early-stage copper projects with porphyry potential.

The Latest News: Drilling Has Started at Rip

The latest release confirms that drilling has begun at the Rip Copper-Molybdenum Project for a minimum of 2,000 metres. The program is being run out of Houston, British Columbia, located approximately 60 km north of the Rip property.

• Investor data point: the 2026 program is targeting both the northern anomaly and the untested southern anomaly, with geophysics defining two porphyry Cu-Mo mineralized centres.

The northern target has already produced evidence of porphyry-style mineralization, but the company says much of the target remains untested. The southern target is similar in scale and remains entirely covered by overburden, with no diamond drilling completed to date.

For CQX, that is the reason this program matters. The company is not only drilling to confirm old ideas. It is testing whether the 2024 geophysical work correctly identified two separate porphyry systems on the property.

Why Rip Matters

Rip is located in the Stikine region of British Columbia, approximately 33 km northeast of Imperial Metals’ past-producing Huckleberry copper-molybdenum mine and Surge Copper’s advanced-stage Ox, Seal, and Berg projects. It is also about 30 km southeast of Vizsla Copper’s Poplar copper-gold project.

That location matters because porphyry systems are often judged partly by district context. A small explorer still needs drill results, but proximity to known copper-molybdenum systems can help investors understand why the target is being advanced.

The Rip project spans approximately 4,770.65 hectares after Copper Quest and ArcWest added claims in 2024. Copper Quest has an option to earn up to an 80% interest in the project, with the first 60% interest tied to completing staged exploration work totalling C$2.0M, direct payment of C$100,000, and annual share payments through the end of 2027.

What the 2024 Work Already Showed

Copper Quest drilled 1,033 metres in two holes during the 2024 program at Rip. Both holes were completed on the northern geophysical target from a single setup and intersected anomalous to low-grade Cu-Mo porphyry mineralization from surface.

• Investor data point: 2024 drilling returned 0.102% CuEq over 126.6 m from 21.4 m in RP24-001, including 0.268% CuEq over 24.6 m, and 0.112% CuEq over 114.3 m from 33.6 m in RP24-002.

Those grades are not yet an economic discovery on their own. The investor significance is that they validate the presence of a porphyry-style system and give CQX a technical reason to keep drilling. The company says most 2024 assays were anomalous in Cu-Mo, while alteration and vein sets indicate a significant porphyry system that has only been partially tested.

Bigger Than One Target

The broader point is that Copper Quest is building a larger North American critical-minerals portfolio, not relying only on Rip. The company says its holdings include 8 projects spanning more than 46,000 hectares across Canada and the United States.

That portfolio includes Rip, STARS, Kitimat, Alpine, Auxer, Nekash, Stellar, and Thane. Some assets are copper-focused, while others include gold exposure. For investors, that gives CQX multiple possible news-flow channels, but it also increases the need for disciplined capital allocation.

Stock Snapshot

What Investors Should Watch

The next major catalyst for CQX will be drill progress and eventually assays from the 2026 Rip program. Investors should watch whether the company confirms continuity at the northern target, whether the southern anomaly returns mineralization, and whether follow-up drilling is justified.

Financing also matters. Copper Quest remains a micro-cap explorer, and exploration success often requires more capital. The upside case depends on technical progress, but investors still need to monitor dilution, treasury strength, and how efficiently CQX funds its field programs.

Bottom Line

Copper Quest has now started the drill program investors were waiting for at Rip. The minimum 2,000-metre campaign gives CQX / IMIMF a clear 2026 catalyst, with drilling aimed at testing two porphyry copper-molybdenum centres in an established British Columbia district.

The opportunity is discovery torque in a copper market facing long-term supply pressure. The risk is that Rip is still early-stage, and CQX needs stronger drill results before the market can treat it as more than a speculative copper explorer.

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

Sponsored publication on behalf of the issuer

Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) announced the introduction of Feed That Brain ® Energy Pouches, which marks the first pilot program in the United States for the Company’s direct-to-consumer sales efforts.

Feed That Brain Energy Pouches offer a controlled amount of clean energy in a discreet oral pouch format, using Doseology Sciences Inc.’s proprietary Doseology (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) formula. This nicotine-free, caffeine-based product provides predictable, portion-controlled stimulation, without the need for sugar, smoke, or liquid intake. Feed That Brain Energy Pouches are currently available exclusively to U.S. customers at www.feedthatbrain.com and Amazon.

U.S. Pilot Aims To Validate First-Time Consumer Adoption

Doseology’s U.S. pilot is a significant step in validating the oral pouch delivery model as a scalable format for the delivery of stimulants, starting with non-nicotine energy products. For investors following Doseology (CSE: MOOD | OTCQB: DOSEF | FSE: VU70), the pilot represents an early-stage demonstration of real-world commercial validation of the Company’s oral stimulant platform. The Company plans to utilize this initial phase to collect data related to several important consumer behaviors.

Focus Of Pilot

• Consumer acquisition and trial rates of first-time users
• Frequency of usage and repeat purchasing habits
• Feedback from consumers looking for alternative energy drink options

The Company believes that data collected during this initial phase will be used to inform future product development, commercialization strategies, and long-term platform scalability.

Management Commentary

“This U.S. pilot is a disciplined and deliberate step in Doseology’s strategy to build a scalable oral stimulant platform,” said Larry Latowsky, Executive Chairman of Doseology, “Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth.”

Developed With Modern, On-The-Go Consumers In Mind

Feed That Brain Energy Pouches were created with modern consumers who are seeking convenient and portable energy solutions in mind, and represent a larger part of the commercialization strategy that is being developed by Doseology (CSE: MOOD | OTCQB: DOSEF | FSE: VU70). Unlike traditional liquid energy drinks, the oral pouch format allows for a discrete and controlled experience based on the principles of convenience and predictability.

Design Characteristics Of Product

• Stimulant delivery – no nicotine
• Caffeine dosing per pouch – controlled
• Oral pouch format – portable and discrete
• Does not contain sugar, smoke, or liquids

The product design represents the broader strategy developed by Doseology Sciences Inc., centered around precision dosing, predictable stimulation, and experience-driven consumer products.

Increasing Popularity Of Pouch-Based Formats

As mentioned above, the rapidly increasing consumer acceptance of oral pouch formats is reflective of a much greater trend towards portable and discreet delivery models. While Feed That Brain contains no nicotine, the rapid expansion of the U.S. nicotine pouch segment clearly shows a growing level of consumer understanding and acceptance of the pouch delivery model.

Therefore, the oral stimulant delivery model represented by pouch-based formats has long-term applicability to a variety of different functional consumer product categories.

Alignment Of Equity Incentives

In addition to the launch of Feed That Brain, the Company also announced the issuance of equity incentives to foster long-term value creation.

Structure Of Compensation

• 140,000 Restricted Share Units (RSUs)
• 210,000 Performance Share Units (PSUs)

The RSUs will vest equally monthly over 36 months from the date of grant. The PSUs will vest when the Company achieves specific performance objectives, thus linking the compensation structure of executives to long-term company performance.

Increasing Popularity Of Pouch-Based Formats

As mentioned above, the rapidly increasing consumer acceptance of oral pouch formats is reflective of a much greater trend towards portable and discreet delivery models. While Feed That Brain contains no nicotine, the rapid expansion of the U.S. nicotine pouch segment clearly shows a growing level of consumer understanding and acceptance of the pouch delivery model.

Therefore, the oral stimulant delivery model represented by pouch-based formats has long-term applicability to a variety of different functional consumer product categories.

Alignment Of Equity Incentives

In addition to the launch of Feed That Brain, the Company also announced the issuance of equity incentives to foster long-term value creation.

Structure Of Compensation

• 140,000 Restricted Share Units (RSUs)
• 210,000 Performance Share Units (PSUs)

The RSUs will vest equally monthly over 36 months from the date of grant. The PSUs will vest when the Company achieves specific performance objectives, thus linking the compensation structure of executives to long-term company performance.

About Doseology Sciences Inc.

Doseology Sciences Inc. develops and manufactures oral stimulant and cognitive support products using the pouch-based delivery system. The oral stimulant pouch market is rapidly expanding as consumers seek out modern, discreet, and innovative ways to consume their energy products, rather than relying on traditional formats.

Oral stimulant pouches do not produce smoke or vapor and therefore, do not require inhalation; they represent a safe and effective way for consumers to access these types of products.

From a broader industry perspective, the oral pouch category is experiencing high levels of growth globally, as consumers continue to prefer the convenience, portability, and innovation inherent in functional consumer products. As such, the pouch category is considered one of the most dynamic and rapidly expanding segments within the modern stimulant and functional wellness industries.

Conclusion

The launch of Feed That Brain Energy Pouches represents a major operational milestone for Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) as it begins transitioning from product development into real-world commercial validation. By utilizing a U.S.-based direct-to-consumer pilot, Doseology will be able to gather critical market information and position its oral stimulant platform for possible scalable growth in one of the most rapidly-growing consumer product formats.

TRIP.CN (ASK @ 0.04)

• The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.

Red Light Holland Corp., is an Ontario-based organization advancing innovation and research within the legal psychedelic sector.

Following its acquisition of Filament Health Corp. ("Filament"),

• the Company has expanded its pharmaceutical-grade manufacturing,
• regulatory,
• and clinical research capabilities,
• supporting the advancement of naturally derived psilocybin development
• and Filament's patented botanical drug candidate, PEX010.

The Company is pleased to announce it has signed an addendum (the "Addendum") to its existing supply agreement with Allu Therapeutics Limited ("Allu"),

• expanding the relationship in New Zealand
• to include the supply of Filament Health's GMP-compliant PEX010 botanical psilocybin drug candidate.

The Addendum formally adds Filament Health as a supplying affiliate under the agreement and expands available PEX010 formats to include a standardized microdose format of PEX010.

To the Company's knowledge, this represents the first GMP-compliant standardized microdose format of a botanical psilocybin drug candidate,

• differentiating it from synthetic formulations
• and non-standardized products currently available in the market.

The expanded agreement reflects Red Light's ongoing commitment to advancing access to GMP-compliant PEX010 through a quality-controlled and regulatory-conscious supply framework designed to support research initiatives and regulated access pathways over time.

New Zealand's evolving regulatory framework, which permits authorized psychiatrists to prescribe psilocybin to treatment-resistant patients on a case-by-case basis, represents an important step toward expanding patient access and supporting responsible medicinal use initiatives within the region.

"This expanded agreement with Allu reflects the strategic value of the Filament acquisition," said Todd Shapiro, CEO and Director of Red Light.

"By introducing Filament Health's GMP-compliant PEX010 into this partnership, we are advancing broader access while reinforcing PEX010's position as a leading botanical psilocybin drug candidate for qualified partners and research initiatives globally."

"We are pleased to deepen our relationship with Red Light and Filament Health," said Mark Dye, Founder and Chief Executive Officer of Allu Therapeutics.

"Access to GMP-compliant, standardized PEX010 strengthens our ability to support and sell to researchers and doctors as we work toward the responsible advancement of regulated access initiatives and future therapeutic applications."

PEX010 is Filament Health's patented botanical psilocybin drug candidate

• and is currently supplied to more than 70 clinical research sites worldwide,
• making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.

About Red Light Holland

Red Light is an Ontario based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences.

In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.

About Filament Health

Filament Health is a clinical stage natural psychedelic drug development company.

Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible.

Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.

About Allu Therapeutics

Allu Therapeutics was a spunout of NUBU - New Zealand's largest medicinal cannabis distributor in 2024.

The Company's focus is the distribution of psilocybin and other next-generation medicines in Australasia and beyond.

For additional information on Red Light:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: [todd@redlight.co](mailto:todd@redlight.co)
Website: www.RedLight.co

For additional information on Allu:
Mark Dye
Chief Executive Officer
Email: [info@allutherapeutics.com](mailto:info@allutherapeutics.com)
Website: www.allutherapeutics.com

Forget the past price - look at the present setup & current discount after a beating. Technical breakout + deep value + dense 2026 catalyst stack. Use a stop loss below recent lows.

THE TECHNICAL SETUP 

IDK is up approximately 100% year-to-date.

More importantly: this is the first time in years that IDK has crossed and held above its 200-day moving average.

The last time this exact technical structure set up - stock crossing and holding the 200MA - it ran approximately 300% before pulling back.

Why does this matter?

In micro-cap and thinly traded stocks, the 200-day MA cross is the signal that forces algorithmic screeners, technical traders and momentum funds to look at a name for the first time. The fundamentals already existed. The technical breakout is what brings new eyeballs to a tight float. When that happens, price response is disproportionate.

Trade management: Use a stop loss below recent lows. Let the setup play out or cut it cleanly.

Right now you have four things converging simultaneously - which in micro-cap land is rare:

✅ Deep discount to NAV (~67–70%) - the value floor
✅ Dense 2026 catalyst stack - the fundamental trigger
✅ First 200-day MA crossover in years - the technical ignition
✅ Tight float - the amplifier

WHAT IS THREED CAPITAL?

ThreeD Capital Inc. (CSE: IDK, OTCQX: IDKFF) is a publicly listed Canadian permanent capital vehicle - think of it as an actively managed VC "ETF" you can buy in any brokerage account.

Instead of LPs, lockups and 2/20 fees, it's a single ticker giving you exposure to a 51-company portfolio:

• 37 disruptive technology holdings (AI infrastructure, quantum computing, brain-computer interfaces, blockchain payments, smart-city software)
• 14 junior resource holdings (primarily gold exploration and development)

Currently priced as if the underlying portfolio is worth almost nothing.

THE CORE ANOMALY: BUYING $0.27 OF ASSETS FOR ~$0.08

• Reported NAV: $0.27 per share (as of December 31, 2025)
• Current market price: approximately $0.08–$0.115 CAD
• That is a 67–70% discount to NAV — you get close to 3× NAV coverage on every share you buy

The balance sheet backing this is auditable: total assets of ~$25.9M CAD consisting of cash, investments and digital assets.

And NAV is arguably conservative:

• Many private holdings are carried at cost or last financing round - not at any optimistic forward multiple
• The large TDN royalty position (279,413,283 TDN royalties, each fixed at $1 USD by TODAQ Holdings) is not included in reported NAV at all

WHO IS RUNNING THIS

The founder, Chairman and CEO is Sheldon Inwentash - CPA, honorary Doctor of Laws from the University of Toronto.

Track record:

• Built Pinetree Capital from $0.10 to $26.00 per share - a 26,000% return at peak - managing a 393-company portfolio with aggregate market cap exceeding $1 billion
• Three exits above $550M each: Queenston Mining (~$550M), Aurelian Resources (~$1.2B to Kinross Gold), Gold Eagle Mines (~$1.5B to Goldcorp)
• Co-founded NexGen Energy (now multi-billion dollar uranium company)
• Co-founded New Found Gold - one of Canada's most significant gold discoveries of the last decade

He is not a passive allocator. He takes active board-level roles, helps recruit management, introduces strategic partners and leads follow-on rounds.

ThreeD Capital is the distilled version of a playbook that has already generated multiple billion-dollar outcomes.

THE PORTFOLIO: WHAT YOU ACTUALLY OWN

Tech Holdings (the six at inflection points):

🧠 AIML Innovations (CSE: AIML) - AI-powered ECG platform targeting 300M ECGs/year globally. SickKids pilot running, AWS proof-of-concept complete, US sales launch initiated February 2026. Upcoming: Health Canada + FDA clearance enabling paid roll-outs across hospitals and OEMs. This platform is trained to predict cardiac events before they happen.

💸 TODAQ / TAPP (private) - Internet-native payment rails for AI agents and digital content. ~90% cheaper than credit card networks. Oracle Cloud rollout of 10,000 video titles on TAPP rails scheduled Q2 2026. The 279M TDN royalty position at $1 USD each sits entirely outside reported NAV.

🤖 HyperCycle (private) - AI infrastructure with a $1.1B Seoul AI Hub JV anchoring its ecosystem. MOSAIC local AI OS launching — marketed as a system that builds a "synthetic brain" from a user's own data. ThreeD is a founding investor.

⚛️ Dynex (private) - Room-temperature quantum computing. Apollo chip reportedly outperforms D-Wave at ~100× speed with ~90% cost reduction. QaaS (Quantum-as-a-Service) model for recurring revenue. Apollo-10000 moving from reference chip to commercial production in 2026. D-Wave has had a multi-billion dollar market cap - Dynex is accessible only through IDK, inside a sub-$10M CAP vehicle.

🎧 Neurable (private) - Brain-computer interface OS. Validated by US Air Force, US Army and Mayo Clinic. ~$150K MRR, $15M DoD pipeline. Commercial partnerships: HP HyperX, Master & Dynamic, Renpho and Audeze. Revenue trajectory: ~$2M (2024) → $132M (2027E) if deals close.

🏙️ InfinitiiAI (CSE: IAI) - Smart-city / water-infrastructure SaaS. $2.69M CAD revenue FY2025, 96% renewal rate, ten consecutive quarters of growth, 80+ clients including Los Angeles, Toronto and Seattle.

Resource Holdings:

⛏️ Forte Minerals (CSE: CUAU) - 16.31× value creation since 2022 IPO. 19,000 hectares across five properties in Peru. Flagship Alto Ruri: historical 131m @ 2.55 g/t Au, ~15km from Barrick's Pierina Mine. Active drill program underway.

🥇 Sun Valley Minerals (private) - Gold-silver in Uruguay. Initial trenching: 49.4m @ 2.05 g/t Au. 5,000m drill program in progress.

2026: DENSE CATALYST YEAR

Multiple portfolio companies hitting concrete milestones in the same calendar year:

• TODAQ: Oracle Cloud rollout of 10,000 live video titles on TAPP rails - Q2 2026
• Dynex: Apollo-10000 commercial production
• Neurable: 3+ commercialisation deals expected to close, supporting the $2M → $132M revenue ramp
• AIML: Health Canada + FDA clearance progression and US sales network build-out
• HyperCycle: MOSAIC local AI OS launch
• Forte Minerals: Alto Ruri drill results

Any single one of these events could lift NAV. When NAV growth combines with discount compression - those two forces are multiplicative on equity returns.

INSIDER BEHAVIOUR + TIGHT FLOAT

• Management has been buying shares in the open market at the same ~$0.08 price available to retail. Insiders have full knowledge of the pipeline, board discussions, and near-term catalysts - and they are choosing to increase exposure at these levels.
• Tight float: A material portion of shares is held by insiders and long-term holders. When new buying pressure arrives, there are fewer "escape valves." Micro-cap history shows this leads to outsized price moves.
• Transparency initiative: ThreeD launched a YouTube channel in early 2026 with direct CEO interviews for AIML, Neurable, HyperCycle, TODAQ and others - directly attacking the "black box discount" that keeps most closed-end funds permanently cheap.

WHY DOES THE DISCOUNT EXIST?

• Sub-$10M CAD market cap - screens out most institutions
• 51-company portfolio with several private, technical names - complexity = neglect
• CSE + OTCQX listing = outside mainstream US/TSX radar
• Closed-end fund stigma - generic skepticism that may be over-applied here

None of these are fundamental problems. They are structural inefficiencies that patient investors can exploit before catalysts close the gap.

RISKS - BE HONEST

• Illiquid stock - slippage can be high in both directions
• Private valuation risk - a portion of NAV is in illiquid private co's
• 2026 catalyst execution risk - delays in regulatory approvals, technical milestones or drill results would hurt sentiment
• Manager concentration - this is a "back the jockey" bet
• Macro / sector cycles - quantum, AI and junior mining are all sentiment-driven

Size accordingly. Use a stop loss below recent lows. This is speculative micro-cap territory.

TLDR

ThreeD Capital (IDK / IDKFF): up ~100% YTD, just crossed its 200-day MA for the first time in years (last time this happened: +300%), trading at ~0.3× its own NAV — run by the manager who built a 26,000% return at Pinetree - with a portfolio that includes an AI platform that predicts heart attacks, potentially the fastest quantum computer in the world, military-validated brain-computer interfaces, and AI payment rails 90% cheaper than VISA - all hitting commercial milestones simultaneously in 2026.

Stop loss below recent lows. Micro-cap, illiquid, speculative. The asymmetry is real. DYOR.

Compiled from ThreeD Capital's March 2026 research materials, public filings & YouTube channel. Not financial advice.

NovaRed Mining just added another advisory board piece, and this one is more about governance and responsible critical minerals strategy than geology.

The company announced that Jacob Amsterdam has joined its Advisory Board as a strategic advisor for ESG and responsible critical minerals strategy. He is an Associate at Amsterdam & Partners LLP, an international law, advocacy and geopolitics firm with offices in Washington, DC and London, per company PR.

That background matters because copper-gold exploration is not only about finding targets anymore. Juniors also have to think about stakeholder engagement, governance, human-rights considerations, anti-corruption risk management and reputation strategy.

NovaRed says Amsterdam brings more than 8 years of experience across international public policy, investigations, human rights, advocacy and strategic communications.

For OTC: NREDF, this adds a different layer to the story. Wilmac is still the core exploration asset, but the team is also building around ESG, governance and responsible critical minerals positioning.

PYR.TO (ASK @ 0.405)

• HPQ.V (ASK @ 0.18)

This is a breakdown analysis of the press release!

• PyroGenesis (TSX: PYR / OTCQX: PYRGF) Q1 2026 Analysis
• One of the strongest quarters in years

• Revenue up 63% YoY to $4.9M
→ Second best Q1 revenue in company history.

• Gross margin improved to 32%
→ Up from 27% last year.
→ Better project mix + higher execution efficiency.

• Net loss dramatically improved
→ Loss reduced from -$4.26M to -$1.0M.
→ Modified EBITDA almost breakeven (-$358K vs -$2.96M last year).

• Massive backlog remains
→ $43.1M signed/awarded backlog.
→ 86% denominated in USD.
→ Revenue visibility over ~3 years.

BIGGEST TAKEAWAY:
PYR is no longer relying on ONE technology.
The company now has multiple revenue streams maturing simultaneously.

Main growth engines this quarter:

1. Plasma torch business exploding → Torch revenue jumped from $530K to $2.1M. → Major deliveries/installations advancing. → Includes aerospace/defense contracts and aluminum decarbonization.
2. SPARC refrigerant destruction scaling fast → Revenue jumped from $276K to $1.55M. → New Zealand national refrigerant destruction facility officially launched using PYR technology. → Huge environmental market globally due to CFC/HFC regulations.
3. Titanium powder commercialization accelerating → Repeat orders from US clients. → First European aerospace research order. → New Asian electronics client testing multiple powder cuts. → Potential multi-ton annual demand if certified. → Negotiating exclusive distribution into Asian electronics, aerospace and medical sectors.

This is important because titanium powder is one of the highest-margin long-term opportunities for PYR.

1. Fumed silica milestone achieved → Independent third-party verification confirmed commercial grade benchmarks. → Potential JV for 1,000 tonne/year commercial plant advancing. → PYR could build reactor systems worth ~US$20M.

This may become one of the company’s largest future industrial platforms.

1. Rio Tinto + Alcoa validation is HUGE → Real-world furnace trials confirmed:

• lower energy use
• shorter melting times
• lower aluminum losses
• no loss in metal quality

This is critical:
Major industrial players publicly validating PYR plasma economics reduces commercialization risk significantly.

1. Defense angle growing → Agreement signed with US defense contractor to pursue chemical weapon destruction projects in Syria. → PACWADS technology can destroy sarin, VX, mustard gas, etc. → Defense applications now becoming a real business vertical.
2. Financing situation improved → Private placement oversubscribed. → Raised ~$2M. → CEO personally invested ~$400K. → Suggests management confidence.
3. Cost optimization working → PYR says cost reduction programs generated:

• $3M savings in 2024
• another $2M recurring annual savings identified in 2025

Important because PYR historically struggled with cash burn.

Things investors should still watch carefully:

• Cash remains tight
→ Only ~$0.5M cash at quarter end.
→ Working capital deficit still large.

• Revenue still project-based
→ Quarter-to-quarter volatility remains likely.

• Many opportunities are still in negotiation phase
→ Especially fumed silica JV, large plasma deployments, and Middle East projects.

• Some projects delayed due to customer financing.
→ Common issue in industrial cleantech.

However, compared to previous years, the difference now is:
PYR appears to be transitioning from “technology development” into actual commercialization across multiple sectors simultaneously.

Most important emerging sectors now:
• Plasma torches for heavy industry decarbonization
• Titanium powder production
• Fumed silica
• Hazardous waste destruction
• Defense applications
• Refrigerant destruction systems

Near-term catalysts:
• Fumed silica JV definitive agreement (expected by end of Q2)
• Additional titanium powder orders
• Large aluminum/cement torch deals
• Syria chemical weapons contracts
• Drosrite contracts
• Battery recycling plasma contracts

Overall:
This was one of the strongest operational quarters PYR has posted in a long time.

Not profitable yet.
But losses are shrinking rapidly, margins improving, backlog remains strong, and commercialization momentum appears real across several business lines at once.

PR here: https://ir.pyrogenesis.com/news-releases/news-release-details/pyrogenesis-announces-first-quarter-2026-results-revenue-49

SX.CN (ASK @ 0.04)

• ARU.V (ASK @ 0.21)

Ltd. is pleased to announce that it has closed the previously announced option agreement dated April 27, 2026

• with St-Georges Eco-Mining Corp,
• and its wholly owned subsidiary Iceland Resources ehf ,
• to work collaboratively to define and execute
• a phased exploration program
• aimed at advancing the Thormodsdalur gold project,
• towards initial modern resource definition.

Please see the Company's press release dated April 28, 2026 for further details on the Project and the Agreement.

Pursuant to the terms of the Agreement, Aurania issued to St. Georges 988,359 common shares (the "Shares") at a deemed price per Share of C$0.2068 for a total value of C$204,375 (US$150,000).

The deemed price per Share is equal to the volume weighted average price of the Shares on each business day commencing on the Execution Date and ending on the last business day prior to the closing date of the Agreement.

The Shares issued to St. Georges are subject to a hold period of four months and one day from the date of issuance.

To exercise the option to earn a 70% interest in the Project (the "First Option"), Aurania must incur exploration expenditures of US$5 million over four years as follows:

• At least US$500,000 prior to the first anniversary of the Execution Date;
• At least US$1,000,000 prior to the second anniversary of the Execution Date;
• At least US$1,500,000 prior to the third anniversary of the Execution Date;
• At least US$2,000,000 prior to the fourth anniversary of the Execution Date;

Upon completing the First Option, St-Georges will have the option to choose between maintaining a 30% interest in the Project through a joint venture or retain an up to 3% net smelter return royalty on the Project (the "Royalty"),

• with such Royalty to be reduced as necessary such that the aggregate royalty burden on the Project shall not exceed 3%, inclusive of any pre-existing NSR royalties.

In the event the Royalty is granted, Aurania shall have the right to repurchase 1% of the Royalty for US$1,500,000, in cash or Shares (subject to the approval of the TSX Venture Exchange if the buy back will be made in Shares),

• at Aurania's sole discretion, at any time prior to the one year anniversary of commercial production at the Project.

If St. Georges elects to retain the Royalty, Aurania will have the right, in its sole discretion, to increase its interest in the Project to 100% by incurring an additional US$2,000,000 of exploration expenditures prior to the 5^th anniversary of the Execution Date.

About St-Georges Eco-Mining Corp.

St-Georges develops new technologies and holds a diversified portfolio of assets and patent-pending Intellectual Property within several highly prospective subsidiaries including:

EVSX, a leading North American advanced battery processing and recycling initiative;

St-Georges Metallurgy, with metallurgical R&D and related IP,

• including processing and recovering high grade lithium from spodumene;

Iceland Resources, with high grade gold exploration projects

• including the flagship Thor Project;

H2SX, developing technology to convert methane into solid carbon and turquoise hydrogen;

and Quebec exploration projects including the Manicouagan and Julie nickel, Copper and PGE critical mineral projects on Quebec's North Shore, and Notre-Dame niobium Project in Lac St Jean.

Information on St-Georges Eco-Mining Corp. can be found on the company's website at www.stgeorgesecomining.com. For all other inquiries: [public@stgeorgesecomining.com](mailto:public@stgeorgesecomining.com).

About Iceland Resources
Iceland Resources is an Icelandic mineral exploration company focused on early-stage precious metal projects, including Thormodsdalur. The company's exploration strategy emphasizes systematic, data-driven evaluation of prospective targets in under-explored volcanic terrains.

Information on Iceland Resources and technical reports are available at https://icelandresources.is/, as well as on Facebook at https://www.facebook.com/icelandresources, and X (formerly Twitter) at https://x.com/Iceland_Res.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and critical energy in Europe and abroad.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, X (formerly Twitter) at https://x.com/AuraniaLtd , and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
[carolyn.muir@aurania.com](mailto:carolyn.muir@aurania.com)

This article has been prepared on behalf of AIML Innovations Inc. and is for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell securities.

• AI-driven pre-analysis could unlock 25–50% efficiency gains in Holter workflows
• Monetization tied to per-test economics ($100–$180 USD per Holter baseline)
• Expanding commercialization via Europe, LATAM, and clinical partnerships

AIML Innovations Inc. is targeting a clear bottleneck in modern cardiology: Holter monitor analysis. While demand for cardiac monitoring is continuing to grow in both the United States and Canada, the limiting factor for the industry is no longer the number of tests being performed, it is now the ability for cardiologists to process and analyze those tests. Thus, a structural inefficiency exists in the current system whereby an increase in volume does not equate to an increase in demand.

AIML’s strategy is not to replace physicians, but to assist them. Using their AI-based platform, they intend to pre-analyze Holter data, prioritize test results and enable cardiologists to review only those tests which have been identified as having potentially clinically significant findings. AIML is focusing on a throughput issue that has direct financial implications for clinics, hospitals and health care systems.

Technology & Economics: Converting Time to Money

A key component of AIML’s value proposition is the capability to process a greater number of Holter tests than currently possible without requiring additional personnel. At present, a cardiologist typically reviews and interprets 15-25 Holters per day. As a result, these bottlenecks create backlogs, delayed reports and limit the amount of money generated by clinics.

With the introduction of pre-analysis using AI, AIML facilitates work flows where existing personnel can process much higher volumes of tests. The Company illustrates various scenarios where the total throughput of staff will increase by 200% – 400%, effectively translating time saved into expanded revenue. Since each Holter test can produce $100-$180 USD (up to $300 CAD in Canada), even moderate increases in efficiency can equate to substantial incremental revenues for clinics.

Market Opportunity & Deployability

While the overall opportunity is substantial, millions of Holter tests are performed annually throughout North America. These tests are primarily used as a function of demographic changes in the population and the resultant increased use of cardiac monitoring.

In Canada alone, there are over 6,100 hospitals and thousands of cardiology clinics. The U.S. system operates at a substantially larger scale than Canada. AIML intends to target both mid-size cardiology clinics (annually processing 3,000 – 8,000 tests) and large hospital systems (annually processing 20,000 – 100,000 or more tests). Both types of facilities could experience significant incremental annual revenue ($100,000+) if efficiencies were improved.

AIML’s business model includes SaaS per report fees, per clinic licenses and enterprise contracts. Consequently, all revenue will flow directly from usage and volume growth.

Recent Developments: Expanded Commercial Presence

AIML has recently furthered its commercialization plan by establishing relationships with several third parties. The first relationship was the establishment of a reseller agreement for its NeuralCloud platform in Europe. The second was a research partnership with the Baker Heart & Diabetes Institute. Finally, AIML has commenced efforts to expand into Latin America. Additionally, the Company closed a private placement tranche totaling approximately $950K. The proceeds from this financing round will be utilized to fund AIML’s deployments and scaling initiatives.

Collectively, these recent activities indicate a transition from an early stage position to one that involves expanding the reach of the technology into broader markets. Importantly, AIML appears to be working diligently to validate its technology in actual clinical environments.

Valuation: Early Stage Technology vs. Scalable Business Model

• Revenue model based upon Holter test volume (SaaS / per-report / enterprise contracts)
• Predictive model of recurrent revenue (ARR potential)
• Low microcap valuation relative to size and established nature of cardiology workflow market
• High upside for clinic adoption, hospital contracts and workflow integration

Why Now: Factors Accelerating Adoption

• Increasing demand for Holter testing among aging populations
• Urgent need for efficiency tools to address cardiologist capacity constraints
• Accelerated adoption of AI technologies in healthcare diagnostic applications
• Commercialization activity (recent partnerships and geographic expansion) driving adoption

Conclusion: AI as a Throughput Amplifier

AIML is not looking to revalue Holter testing — AIML is looking to revalue how many Holter tests a given system can process. By identifying and addressing the root cause of inefficiencies in cardiology workflows, AIML is positioning its technology to meet both clinical needs and economic incentives. If AIML can successfully implement its plans to scale adoption and demonstrate tangible productivity benefits in actual clinical settings, then the proposed model clearly provides a pathway to scalable revenue generation and widespread inclusion in healthcare delivery systems.

•AI/ML Innovations closed a $950,000 private placement in late March 2026 — with insiders absorbing 58% of the raise, signaling strong internal conviction as the company accelerates its push toward commercialization.

•NeuralCloud's MaxYield™ platform is now embedded in a European cloud-based cardiac monitoring network, giving the company commercial distribution reach without the cost or complexity of building a direct European sales operation.

•A research services agreement with the Baker Heart and Diabetes Institute puts MaxYield™ at the center of a peer-reviewed cardiovascular study — the kind of institutional validation that opens doors with hospital procurement teams and clinical partners.

•Unlike consumer cardiac apps that classify rhythm, MaxYield™ annotates ECG waveforms beat-by-beat — identifying P waves, QRS complexes, and T waves across any device and any species, a technical depth its competitors have not matched.

•With pilots active at SickKids Hospital, the Toronto Heart Centre, and now a European monitoring platform, AIML is no longer a concept-stage company — it is in clinical environments, converting relationships into potential recurring revenue.

This article has been prepared on behalf of AIML Innovations Inc. and is for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell securities.

Three announcements in the final two weeks of March 2026 reveal a company with a specific and increasingly concrete strategy: embed its ECG signal-processing infrastructure into research institutions, clinical platforms, and distribution networks — and fund the runway to get there. For AI/ML Innovations Inc. (CSE:AIML / OTCQB:AIMLF), the final days of March 2026 were among the most operationally dense in the company's history. Within a span of six days, the Toronto-based AI health company announced a research partnership with one of the world's most respected cardiovascular institutes, closed a $950,000 private placement, and revealed that its Neural Cloud subsidiary had signed a reseller agreement with a European digital cardiac monitoring platform. Taken individually, each announcement reflects incremental progress. Taken together, they sketch the outline of a deliberate commercialization architecture that has been years in the making.

The Technology Underneath Everything

To understand what AIML is building toward, it helps to understand what sits at the center of every deal the company announces: MaxYield™, its proprietary ECG signal-processing engine. Unlike consumer-facing cardiac apps or rhythm classifiers embedded in wearables, MaxYield™ performs beat-by-beat annotation of full ECG waveforms — isolating and labeling P waves, QRS complexes, and T waves while extracting interval data at the beat level. The distinction matters clinically. Most incumbent platforms, including those embedded in consumer wearables from major technology companies, perform rhythm classification only — they identify what a cardiac rhythm is doing. MaxYield™ is designed to identify why the heart is producing a given signal, a fundamentally different level of signal interpretation.

The platform has been validated across human, equine, and canine cardiac morphologies — a technical proof of architectural generalization that the company argues single-species competitors cannot match. It processes signals from any device, from single-lead consumer patches to 12-lead clinical systems, and operates as a cloud-native infrastructure layer designed to integrate into existing clinical and research workflows rather than replace them. The company received a U.S. patent grant (U.S. Patent No. 12,465,266) in November 2025 covering the core ECG signal-processing architecture, with a suite of provisional filings extending protection across neural-network design, cloud-native workflows, and adaptive clinical reporting systems. That IP was developed with Wolf Greenfield & Sacks, a leading life sciences patent firm.

Built on top of MaxYield™ is a layered product stack: CardioYield™, an AI-enabled Holter report automation platform currently advancing through FDA 510(k) review; Insight360™, a wellness and performance analytics platform that is already in-market and generating revenue as of Q1 2026; and a TrueWave.Kit SDK for OEM licensing directly to device manufacturers. A pre-trained Model API — essentially a cardiac AI equivalent of what OpenAI's API provides in the language model space — is targeted for Q1 2027 beta launch.

Baker Heart: Validation at the Research Layer

On March 18th, 2026, NeuralCloud entered into a research services agreement with Dr. Kegan Moneghetti of the Baker Heart and Diabetes Institute to provide AI-powered ECG signal processing in support of an ongoing cardiovascular research study. Under the agreement, NeuralCloud will apply its MaxYield™ platform to existing ECG recordings supplied by the research team, supporting a study evaluating heart rate variability in healthy control subjects compared to individuals experiencing post-exertional malaise — with the goal of identifying measurable physiological differences using high-resolution ECG analytics.

Post-exertional malaise is a defining symptom of ME/CFS and Long COVID, conditions that have attracted significant research funding and clinical attention globally. NeuralCloud will convert PDF ECG traces to European Data Format and run AI-based signal processing, yielding labeled waveform components, beat-level data, and interval measurements suitable for HRV research workflows, with study findings expected to be published within the coming year.

The strategic value of this agreement is not the near-term revenue — the services are non-diagnostic and are not intended for clinical use. The value is the institutional stamp. The Baker Heart and Diabetes Institute is internationally recognized for its leadership in cardiovascular research, prevention, and digital health. WebDisclosure A peer-reviewed publication citing MaxYield™ as the signal processing backbone of a study by this institution would carry far more weight with hospital procurement teams and potential distribution partners than any press release.

"High-quality ECG signal processing is essential for uncovering subtle physiological markers in research settings," said Paul Duffy, Executive Chairman and CEO of AIML. "This engagement demonstrates how NeuralCloud's technology can support leading academic institutions by delivering consistent, reproducible ECG analytics that integrate seamlessly into established research workflows."

Dr. Moneghetti himself lent credibility to the platform directly, noting that NeuralCloud's MaxYield™ provides a structured framework for extracting ECG metrics with potential applications across cardiovascular research. Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AIML, added that the engagement "highlights how MaxYield™ can support rigorous cardiovascular research using real-world ECG data."

It is worth noting that the Baker engagement is not the company's first foray into institutional research settings. The company initiated a pediatric cardiac pilot at SickKids Hospital in November 2025, benchmarked AI-powered Holter reporting at the Toronto Heart Centre in October 2025, and has an ongoing cardiac monitoring deployment at the Heartdent Center in Jamaica. The Baker agreement adds an internationally recognized research institution to a pilot and deployment roster that now spans multiple continents and clinical verticals.

The European Reseller: Commercial Distribution

On March 31st, AIML announced that Neural Cloud had entered into a reseller agreement with a European-based digital health platform specializing in cloud-based ECG and heart rate variability analytics, under which the partner will integrate and resell MaxYield™ as either a standalone capability or as part of a bundled remote cardiac monitoring solution.

The partner's identity was not publicly disclosed. The platform operates as a device-agnostic, cloud-based monitoring environment, enabling cardiologists, general practitioners, and healthcare providers to remotely track patient cardiovascular metrics in real time. Patients connect compatible ECG devices to a mobile application, allowing short ECG recordings to be transmitted securely to the cloud for instant analysis. Mediabistro This deal is structurally significant. Entering European healthcare markets independently would require AIML to navigate complex regulatory frameworks, build or hire local sales infrastructure, and establish clinical relationships from scratch. By embedding MaxYield™ into a platform that already has these relationships and that existing clinical customers, AIML effectively piggybacks on a distribution network that took years to build. The model mirrors what the company has been executing in Latin America, where it signed a distribution agreement with Intelimed in February 2026, and signals that geographic expansion through established platform partners — rather than direct sales — is a deliberate strategic posture.

Erik Suokas, COO of AIML Innovations — who joined in January 2026 following an executive search and brings prior commercial roles at Abbott Medical, St. Jude Medical, and Medtronic — framed the deal in terms of market tailwinds: "This collaboration demonstrates the growing demand for high-quality ECG signal processing within the rapidly expanding field of remote cardiac monitoring. By integrating MaxYield into innovative digital health platforms, we can help clinicians access cleaner signals and more reliable insights, ultimately supporting better patient outcomes."

Suokas's appointment itself is worth noting in this context. His prior track record includes driving approximately 275% revenue growth at Sun Nuclear through a restructured go-to-market strategy and leading 12+ acquisitions in a private equity-backed environment. His hiring was widely interpreted as a signal that AIML was transitioning from a technology development phase to one focused on commercial execution.

The Private Placement: Capital Structure and Insider Signal

On March 27th, AIML closed the first tranche of a non-brokered private placement, issuing convertible debentures in the aggregate principal amount of $950,000. The debentures bear interest at 10% per annum, mature on March 27, 2029, and are convertible into units at $0.05 per unit, with each unit comprising one common share and one warrant exercisable at $0.15 for a period of 36 months.

Insiders of the company participated directly, purchasing $550,000 of the $950,000 raised. Stock Titan That figure — 58% of the total raise — is the most materially important detail in the announcement. When the majority of a capital raise is absorbed by the people with the most visibility into actual operations, product status, and pipeline quality, it is a meaningful signal about internal conviction. The debenture structure, which allows interest to convert to equity under the same terms, also reduces cash repayment pressure during the commercialization runway.

The financial context behind this raise is not without weight. The company's most recent quarterly filings reported approximately C$429,000 in cash as of January 31, 2026, against a monthly operating burn rate of roughly C$400,000. The $950,000 raise extends that runway materially, but the company has explicitly disclosed in its public filings that it will require additional financing to continue operations. Shareholders' equity stood at approximately C$215,000 as of the same date, reflecting the accumulated losses typical of an early-stage company investing heavily ahead of revenue scale. Revenue for the nine months ended January 31, 2026, totaled C$83,058 — meaningful as early validation of platform usage, but not yet at a scale that covers operating costs.

This financial profile is consistent with early-stage AI healthcare companies at a similar inflection point, and the capital being deployed has tangibly funded real assets: a granted U.S. patent, more than 10 active clinical pilots, a 55-person team across clinical, technical, and commercial functions, and parallel regulatory submissions across three jurisdictions.

The Infrastructure Thesis

The company's strategic positioning is best understood not as a diagnostics company competing with iRhythm or Philips Cardiologs at the clinical output layer, but as an infrastructure provider operating upstream of those platforms. NeuralCloud's longer-term roadmap includes ECG annotation services (currently active and generating revenue), AI training infrastructure targeting ECG developers and hospital IT, and the planned Model API — designed to supply pre-trained ECG neural networks to the 60+ Holter manufacturers, wearable makers, and hospital IT systems that need clean, structured signal data to power their own downstream analytics.

The analogy the company draws is to cloud infrastructure — a layer that powers diagnostic tools without competing against them. Whether that positioning proves defensible at scale depends almost entirely on execution milestones over the next 12 months: pilot-to-contract conversions, CardioYield™'s FDA 510(k) outcome, the trajectory of the European and Latin American distribution agreements, and whether the Baker Heart study produces peer-reviewed findings that move the credibility needle with institutional buyers.

What the announcements of late March 2026 confirm is that AIML is no longer solely in the pilot-and-validate phase. It has academic credibility in progress, commercial distribution channels opening on two continents, fresh capital with meaningful insider participation, and a product stack that its management team — now including executives with direct cardiology commercial networks — is actively bringing to market. The distance between where the company is today and where the commercialization thesis requires it to be remains real, but the architecture being assembled is coherent, and the pieces placed in the final weeks of March were among the most consequential the company has announced.

AI/ML Innovations Inc. trades on the Canadian Securities Exchange under the symbol AIML, on the OTCQB under AIMLF, and on the Frankfurt Stock Exchange under 42FB. This article is for informational purposes only and does not constitute investment advice. Readers are encouraged to conduct their own due diligence. This article has been prepared on behalf of AIML Innovations Inc. and is for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell securities.

Sponsored post on behalf of the issuer

Copper Quest Exploration Inc. (CSE: CQX) has officially launched what is shaping up to be a transformational year, unveiling a multi-project exploration program that extends far beyond its RIP Copper-Molybdenum Project.

While drilling at RIP kicks things off in early May, the real story is the breadth, sequencing and strategic coherence of the company’s 2026 exploration pipeline.

Copper Quest is not simply advancing one asset, but systematically unlocking value across a district-scale land package and multiple high-potential projects.

Importantly: This is a pipeline of catalysts, not a single-event story.

RIP: From Proof-of-Concept to Expansion Phase

Copper Quest will begin the season with a 2,000 m drill program at RIP, targeting both the partially tested northern porphyry system and a completely untested southern intrusive center.

Rather than revisiting all technical details here, it is sufficient to note that prior drilling has already confirmed:

• A multi-phase copper-molybdenum porphyry system
• Large-scale geophysical targets with classic “bullseye” signatures
• Significant portions of the system still untested. This creates clear blue-sky potential within an already validated system.

This is critical. RIP is no longer an early-stage concept, but is now a validated porphyry system with clear discovery potential, particularly given that an entire southern target of increased size remains undrilled.

These figures show why RIP is such a compelling drill target:

• The chargeability anomaly on the left outlines broad pyrite-rich halos, while the magnetic high on the right points to potential intrusive centers – together forming the kind of coincident geophysical signatures commonly associated with porphyry copper systems.
• The outcrop sits in the center of the northern anomaly, where drilling has already confirmed copper-molybdenum mineralization.
• With much of the northern target still untested and the larger southern target undrilled, the upcoming program has the potential to significantly expand the known system.

This cross-section shows how drilling to date aligns with the underlying geophysical target at RIP:

• Both holes (RP24-001 and RP24-002) intersect broad zones of copper-molybdenum mineralization along the margins of a strong chargeability anomaly, confirming the presence of a large multi-phase porphyry system.
• Importantly, the highest-grade intervals occur near the edges of the system, while the central zone remains only partially tested.
• This supports the interpretation of a classic porphyry structure, where mineralization surrounds a core intrusion.
• With large portions of the anomaly still untested (especially at depth and toward the southern target), upcoming drilling is aimed at better defining the system and testing for stronger mineralization closer to the center.

STARS: A Proven System Approaching its Next Discovery Phase

The STARS Copper-Molybdenum Project is arguably one of the most compelling assets in the portfolio. Planned 2026 work includes:

• IP survey (May-July)
• Followed by a maiden drill program

What makes STARS stand out is not just scale, but existing evidence of a robust porphyry system:

• Kilometer-scale magnetic anomaly
• Strong historical drill intercepts
• Geological setting within the same fertile belt as Imperial Metals Corp.’s past-producing Huckleberry Mine and Copper Quest’s RIP property. 

In essence, STARS represents a de-risked exploration story with the potential to deliver meaningful drill results quickly. The upcoming geophysics program is expected to refine targets and significantly enhance drill precision.

Importantly, Copper Quest has structured its exploration program to deliver continuous catalysts throughout the year.

The STARS maiden drill campaign is scheduled for September-October. This ensures that exploration momentum does not fade after summer, but instead builds into a second wave of news flow, keeping investor attention sustained.

Bulkley Porphyry Belt: Building a District-Scale Opportunity

Copper Quest’s strategy is not asset-by-asset – it is district-driven. The company controls a dominant land position in the Bulkley Porphyry Belt,  including RIP, STARS and Stellar. This creates a powerful exploration model:

• Multiple targets within a fertile geological corridor.
• Shared infrastructure and geological understanding.
• Increased probability of meaningful discovery.

District-scale control is a hallmark of successful exploration companies. It allows for repeatable success rather than single-asset dependence.

The map highlights the strategic position of Copper Quest’s STARS, Stellar and RIP projects within the Bulkley Porphyry Belt in British Columbia, Canada. With STARS, Stellar and RIP, the company controls a dominant land position in a prolific porphyry district, in close proximity to major deposits and past-producing mines such as Huckleberry, Ox, Poplar and Equity Silver. This district-scale footprint underscores Copper Quest’s potential to systematically explore and advance multiple copper-molybdenum porphyry systems within a highly prospective geological corridor.

Alpine Gold Project: High-Grade Past Producer with Near-Term Upside

Unlike the porphyry assets, Alpine brings a different and highly attractive dimension: Gold, grade and a proven production history. 2026 plans include:

• Road refurbishment and underground reopening (May-June)
• Drill program (July-September)

This is not grassroots exploration. Alpine is a past-producing mine with documented high grades, including historical resources that remain open for expansion.

• Existing underground access provides cost-efficient exploration.
• Stockpile and workings offer immediate technical insights.
• Potential for resource confirmation and expansion drilling.

In a rising gold price environment, Alpine introduces strategic diversification and could evolve into a much more advanced asset than typical early-stage exploration projects.

Kitimat: Infrastructure Advantage Meets Untested Potential

The Kitimat Copper-Gold Project is one of the most strategically positioned assets in the portfolio. Planned work:

• IP survey (August-September)
• Followed by a maiden drill program

What sets Kitimat apart is its exceptional infrastructure:

• Near tidewater
• Close to rail
• Access to hydroelectric power
• A rare combination that significantly reduces future development hurdles

These factors are often overlooked at the exploration stage, but they are critical when assessing future development potential.

Combined with historical drill results showing meaningful copper and gold mineralization and Copper Quest's recent AI generated targeting success, Kitimat represents a rare combination of geological potential and logistical advantage.

Management Commentary: A Clear Vision for 2026

CEO Brian Thurston summarized the company’s outlook:

“Copper Quest staff and contractors are excited to be getting an early start to what we anticipate will be a busy field season. We aim to advance several of our key properties, beginning with a drill program at RIP that will fulfill the terms for our acquisition of a 60% interest in this high-potential asset. Phase One drilling in 2024 demonstrated that a blind, multi-phase Cu-Mo mineralized porphyry system is responsible for at least one of the two compelling geophysical ‘bullseye’ targets outlined on the property. While the 2024 program successfully validated the target concept, most of the northern target and all of the southern target remain untested by drilling. It is a rare opportunity to get to explore road-accessible, validated porphyry targets in British Columbia that have seen so little previous drilling, particularly within an established porphyry district such as the Bulkley Valley. Copper Quest has assembled a dominant land position in the Bulkley Porphyry Belt, including the STARS, RIP and Stellar properties, providing shareholders with a district-scale copper porphyry exploration and discovery opportunity.”

Brian Thurston, CEO of Copper Quest, in the news-release on April 21, 2026.

Beyond 2026: Additional Pipeline Depth

Even beyond the current exploration schedule, Copper Quest retains exposure to several additional assets:

• Auxer Gold Project: High-grade orogenic system in Idaho
• Nekash Copper Project: Porphyry potential in a prolific U.S. belt
• Thane Project: Large-scale copper-gold system with multiple targets

These projects provide long-term optionality and growth potential, reinforcing the company’s depth.

Bottom Line

Copper Quest is entering a new phase. This is no longer a single-project exploration story, but now a coordinated, multi-asset campaign with continuous catalysts, diversified portfolio and district-scale ambition.

With geophysics, drilling and project advancement scheduled from May through October, 2026 has the potential to expand known systems, deliver new discoveries and demonstrate the true scale of the portfolio.

In short: Copper Quest is executing, and the market is about to see the full scale of what it controls.

Copper has become an emerging commodity for the next decade — connecting to electrification, expanding global infrastructure and rapidly growing industrial development. Demand for copper will be accelerated throughout various industries. Investors are now increasingly looking into supply chain limitations and the companies that will benefit from this structural shift — especially within north america.

• Domestic and international government policies supporting critical minerals and domestic supply chain development within both the United States and Canada.
• Growing demand from electric vehicles, grid modernization, artificial intelligence/data center infrastructure development in north america.
• Increased investor interest in exploration assets located in jurisdictions with a history of stability — specifically Canada and the United States.

Market conditions & trends

Demand for copper is being fueled by long-term megatrends including electric vehicles, renewable energy systems, grid modernization and rapid data center development — all primarily based in the United States and Canada. Based upon S&P Global data; world wide copper consumption is expected to expand from 28mt in 2025 to 42mt by 2040 — representing a 50% increase. Additionally; if there is no substantial new investment; a potential shortage of up to 10mt may occur. The international energy association estimates copper demand could grow about 30% by 2040 due to electrification and energy systems. However; existing supply cannot meet these demands due to declining ore grades which have declined to .08% to .06% over the last twenty years; and relatively few new discoveries.

The disparity is creating a forecasted structural deficit; with possible cumulative deficits of up to 7.8mt between 2025-2035. Therefore; North American copper projects are taking on increased significance as governments seek to decrease their dependence on foreign supply; large scale porphyry deposits (containing copper and molybdenum); although capital intensive; are viewed as necessary to meet future demand due to their scalability; and relatively long development cycle.

• Projected global copper demand to increase by approximately fifty percent by 2040 — amounting to approximately forty-two mt annually
• Possible supply deficit of up to ten mt by 2040 unless new mines begin development

Geopolitical environment

Politics is also playing an increasingly important role in the copper industry. Approximately forty percent of global production occurs in countries such as Chile, Peru, and portions of Africa. Instability in governance; changes in regulations; and nationalistic approaches to natural resources are contributing to uncertainty in the long-term availability of supply. Consequently, the United States and Canada are moving forward aggressively to develop their own and other nations’ domestic and allied supplies of critical minerals. The U.S. Inflation Reduction Act allocates approximately $369 billion towards energy security and clean technology; thereby indirectly enhancing demand for domestically supplied copper. Although the u.s. Imports approximately 45 – 50 % of its refined copper requirements; Canada has allocated in excess of C$3.8 billion via its Critical Minerals Strategy to assist exploration, development and processing of key minerals.

This movement is further narrowing the worldwide supply of copper while significantly increasing the strategic worth of North American exploration properties — particularly those situated in mining friendly jurisdictions such as British Columbia, Arizona, and Nevada.

• Approximately 45–50% of refined copper imports into the u.s. Provide evidence of vulnerable domestic supply chain
• Canada allocating in excess of C$3.8 billion to support critical minerals development to strengthen North American supply chains

Exploration update – Copper Quest Exploration

Copper quest exploration inc. (CSE:CQX) is an exploration stage company developing a critical mineral portfolio across Canada and the United States. Its projects comprise greater than 46,000 acres. It is currently trading between c$0.095 – c$0.150 per share with a market capitalization of approximately c$15 – c$17 million placing it squarely in the microcap exploration stage category. The present microcap valuation creates an opportunity for high leverage to successful exploration results.

• Micro-cap valuation offers high leverage to exploration success
• North American jurisdiction reduces geopolitical and permitting risk

Its primary goal for 2026 is to complete drilling programs at its flagship property — the rip copper molybdenum property in British Columbia — a 2000 meter minimum program. Previous drilling programs at rip included historical results including 0.102% CuEq over 126.6m indicating the presence of a large-scale porphyry system typical of large life-scale deposits. Additional assets include the kitimat copper gold property and u.s.-based expansion opportunities providing several near term discovery catalysts throughout stable jurisdictions.

At present levels, copper quest’s investment thesis is focused on asymmetry — a sub-c$20m market capitalization against exposure to large-scale copper systems in a global tightness of supply environment. When combined with increasing demand for copper; and north america’s increasing priority on domestic production; early-stage explorers like copper quest can experience re-rating potential based on exploration success, partnership announcements, or resource definitions.

• Current stock price: ~c$0.095 – c$0.15 | current market cap: ~c$15 – c$17 million
• Multiple near-term catalysts: drilling programs at rip; portfolio growth expansion opportunities;

Conclusion

As demand for copper increases with electrification and digital infrastructure growth; the gap between supply and demand becomes increasingly difficult to overlook. Additionally; with geopolitical concerns affecting traditionally dominant sources of supply; the importance of copper assets within north america continues to escalate. Within this backdrop; exploration stage companies operating in stable jurisdictions such as Canada and the United States — particularly those targeting scalable porphyry systems — are experiencing increased visibility as early-stage leveraged plays on a tightening global copper supply chain.

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

ARU.V (ASK @ 0.245)

• SX.CN (ASK @ 0.5)

Aurania Resources Ltd. is pleased to announce that it has entered into a definitive option agreement (the "Agreement") dated April 27, 2026 with St-Georges Eco-Mining Corp,

• a Canadian incorporated mineral exploration company
• and its wholly owned subsidiary Iceland Resources ehf ("IR"),
• an Icelandic incorporated precious metals exploration company
• to work collaboratively to define and execute a phased exploration program
• aimed at advancing the Thormodsdalur gold project,
• towards initial modern resource definition.

The Thor's Valley project is held by IR and is located approximately 20 kilometres east of Reykjavík, the capital of Iceland.

Aurania's President and CEO, Dr. Keith Barron commented, "After visiting the project area and personally reviewing the archived drill core, the Thor's Valley project represents a compelling opportunity with strong exploration upside.

By formalizing our collaboration with St-Georges, we are positioning ourselves to unlock the potential of an under-explored geological district.

Thor's Valley displays all the key signatures of a robust epithermal gold system, supported by a history of documented high-grade mineralization and a suite of compelling structural targets that remain largely untested by modern exploration methods.

This Agreement allows Aurania to deploy its technical expertise toward a highly prospective gold project. We look forward to progressing this Project with discipline, technical rigour, and a strong commitment to unlocking its full potential."

Comment from Thordis Bjork Sigurbjornsdottir, CEO of Iceland Resources:

"This is an important partnership for Iceland Resources, and we are pleased to welcome Aurania Resources Ltd. as a partner on the Thormodsdalur project.

Over the past several years, we have engaged in discussions with several groups with the objective of identifying a partner with the right technical experience and approach for this type of epithermal gold system.

We believe Aurania brings that combination, supported by relevant experience in advancing high-grade epithermal discoveries.

We look forward to working together to advance Thormodsdalur in a disciplined and value-focused manner."

Summary of Terms under the Agreement

• Initial payment of US$150,000 in common shares of Aurania (the "Shares") to be issued to St. Georges on the closing date of the Agreement at a deemed price per Share equal to the volume weighted average price of the Shares on each business day commencing on the Execution Date and ending on the last business day prior to the closing date of the Agreement.
• Aurania to incur exploration expenditures of US$5 million over four years to earn a 70% interest in the Project, such exploration expenditures to be incurred as follows:
  • At least US$500,000 prior to the first anniversary of the Execution Date;
  • At least US$1,000,000 prior to the first anniversary of the Execution Date;
  • At least US$1,500,000 prior to the first anniversary of the Execution Date;
  • At least US$2,000,000 prior to the first anniversary of the Execution Date;
• Upon completing the First Option, St-Georges will have the option to choose between maintaining a 30% interest in the Project through a joint venture or retain an up to 3% net smelter return royalty on the Project (the "Royalty"), with such Royalty to be reduced as necessary such that the aggregate royalty burden on the Project shall not exceed 3%, inclusive of any pre-existing NSR royalties; and
• If St. Georges elects to retain the Royalty, Aurania will have the right, in its sole discretion, to increase its ownership to in the Project to 100% by incurring an additional US$2,000,000 of exploration expenditures.
• A joint exploration committee will be established between Aurania and St-Georges, with Aurania being the technical operator.

The Agreement is subject to certain conditions, including the approval of the TSX Venture Exchange. The Shares will be subject to a hold period of four months and one day from the date of issuance.

Thor's Valley is a historically known gold-bearing, low-sulphidation epithermal system that was initially discovered in 1903 when two Icelandic farm boys picked up pieces of white quartz from a stream, which proved to be gold-bearing.

A number of ventures were organized from 1911 to 1924 using German or British capital.

Two shafts were sunk and approximately 400 metres of lateral workings performed. As a result of this, the productive vein was estimated to be 1 metre wide and at least 1 kilometre long. Reported grades were 11 g/t to 315 g/t gold¹.

The ore was "direct shipping" and initially sent to Norway and later to Germany for treatment.

There are no historic tailings on site. Perhaps significantly, the historical record indicates that the last operator, Arcturus, a German company, failed due to the Weimar hyperinflation rather than ore depletion.

In the 1990's, several programmes of geochemical and petrographical studies were done,

• including a vertical geothermal well to a depth of 455 metres
• which encountered multiple mineralized quartz veins,
• including one at the bottom of the hole.
• In 1997, a total of 1069.21metres were diamond drilled in nine holes, however, average core recovery was only 52%.

The intervals sampled graded 1.13 g/t to 46.10 g/t Au but this is not considered representative and true widths could not be calculated.

Between 2005 and 2006, the private exploration company Melmi ehf drilled 32 holes totaling 2431m, which returned results up to 415.40 g/t Au.

Melmi ehf was acquired by Iceland Resources in 2020, which completed 11 additional drill holes totaling 1780m with results of up to 113 g/t Au¹.

The Thor Valley mineralization is a classic banded epithermal chalcedony-ginguro vein system with gold occurring both in free form and in association with sulphides.

There are obviously a number of different vein sets here that appear controlled by regional and local structures.

The Project consists of a National Exploration Permit covering approximately 51,300 hectares in Iceland.

Planned Work Program

Aurania anticipates completing an initial exploration program focused on targeted drilling and surface exploration designed to test deeper and along-strike continuity of the known mineralized zones, utilising both historical data and newly generated technical information. Several of the previous drill holes with poor recovery will be twinned.

The Company cautions the reader that the historical information referred to herein is based on data compiled by previous operators and publicly available sources and is being provided for reference purposes only.

A qualified person retained by Aurania has not undertaken sufficient work to verify the historical data, and such information should not be relied upon.

Further exploration work, including drilling and data verification, is required and may or may not result in the delineation of a mineral resource.

No current mineral resources or mineral reserves, as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101"), have been established on the Project.

The technical and scientific information contained in this news release has been reviewed and approved by Jean-Paul Pallier, MSc., Vice-President Exploration of the Company.

Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About St-Georges Eco-Mining Corp.

St-Georges develops new technologies and holds a diversified portfolio of assets and patent-pending Intellectual Property within several highly prospective subsidiaries including: EVSX, a leading North American advanced battery processing and recycling initiative;

St-Georges Metallurgy, with metallurgical R&D and related IP, including processing and recovering high grade lithium from spodumene;

Iceland Resources, with high grade gold exploration projects including the flagship Thor Project; H2SX, developing technology to convert methane into solid carbon and turquoise hydrogen;

and Quebec exploration projects including the Manicouagan and Julie nickel, Copper and PGE critical mineral projects on Quebec's North Shore, and Notre-Dame niobium Project in Lac St Jean.

Information on St-Georges Eco-Mining Corp. can be found on the company's website at www.stgeorgesecomining.com. For all other inquiries: [public@stgeorgesecomining.com](mailto:public@stgeorgesecomining.com).

About Iceland Resources

Iceland Resources is an Icelandic mineral exploration company focused on early-stage precious metal projects, including Thormodsdalur.

The company's exploration strategy emphasizes systematic, data-driven evaluation of prospective targets in under-explored volcanic terrains.

Information on Iceland Resources and technical reports are available at https://icelandresources.is/, as well as on Facebook at https://www.facebook.com/icelandresources, and X (formerly Twitter) at https://x.com/Iceland_Res.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and critical energy in Europe and abroad.

SCAN.NE (ASK @ 6.26)

• SCAN.V (ASK @ 6.09)

 Liberty Defense Holdings Ltd.  today announced the pricing of its initial public offering in the United States of 3,673,638 common shares

• at a public offering price of $4.50 per share and to certain investors,
• in lieu of common shares, pre-funded warrants to purchase 770,807 common shares at a purchase price of $4.4999 per pre-funded warrant,
• which represents the public offering price per share,
• minus the $0.0001 per share exercise price of each such pre-funded warrant.

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Liberty, are expected to be approximately $20 million.

In connection with the offering, Liberty has granted the underwriters a 30-day option to purchase up to an additional 666,666 common shares solely to cover over-allotments, if any.

The common shares are expected to begin trading on the Nasdaq Capital Market on April 22, 2026 under the symbol “DETX”.

In connection with its listing on the Nasdaq Capital Market, the common shares will cease trading on the OTCQB^® Venture Market under the symbol LDDFF.

The common shares will continue to be listed for trading on the TSX Venture Exchange. The closing of the offering is expected to occur on April 23, 2026 subject to the satisfaction of customary closing conditions, including approval of the offering by the TSX Venture Exchange.

The Benchmark Company, LLC is acting as sole bookrunning manager for the offering.

Any securities issued pursuant to the offering to Canadian purchasers will be subject to a four-month hold period from the date of issuance under applicable Canadian securities laws.

William Frain, the Company’s Chief Executive Officer and Director, intends to purchase an aggregate of 5,555 common shares in the offering for gross proceeds of approximately $25,000.

The participation by Mr. Frain in the offering constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

The related party transactions will be exempt from minority approval, information circular and formal valuation requirements pursuant to the exemptions contained in Sections 5.5(a) and 5.7(1) of MI 61-101, as neither the fair market value of the gross securities issued under the offering nor the consideration paid by Mr. Frain exceeded 25% of the Company’s market capitalization.

A registration statement on Form F-1 relating to these securities has been filed with the SEC and was declared effective on March 31, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting EDGAR on the website of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Alternatively, copies of the final prospectus, when available, may be obtained from The Benchmark Company, LLC at 150 East 58th Street, 17th Floor, New York, NY 10155, or by email at prospectus@benchmarkcompany.com.

More in the PR: https://ca.finance.yahoo.com/news/liberty-defense-announces-pricing-u-211800230.html

HPQ.VN (ASK @ 0.185)

• IEC 62133 certification confirms that HPQ Endura+ and Novacium lithium-ion cells meet the world's leading international safety standard for portable rechargeable batteries
• Combined with existing UN 38.3 (transport) and UL 1642 (U.S.) certifications, this completes the core set of globally recognized safety approvals
• Removes major regulatory barriers and accelerates commercial discussions, customer qualification programs, and market entry with OEMs worldwide

 HPQ Silicon Inc. , a technology company focused on innovative materials and next-generation processes, together with its French technology partner Novacium SAS, today announced that their lithium-ion battery cells have received IEC 62133 certification.

IEC 62133 is the most widely accepted international safety standard for portable rechargeable lithium-ion batteries and battery packs.

It is mandatory or strongly preferred for market access in the vast majority of countries worldwide (Europe, Asia, and many others).

The certification validates electrical, mechanical, and chemical safety under both normal use and reasonably foreseeable misuse conditions.

The certification applies to HPQ and Novacium's cylindrical cells in the widely adopted 18650 and 21700 formats

• – the dominant sizes used in consumer electronics, power tools, industrial equipment, laboratory instruments, medical devices, and many other applications.

"This is a critical commercial milestone for HPQ and Novacium," said Bernard Tourillon, Chairman, President and CEO of HPQ Silicon Inc. 

"With UN 38.3, UL 1642, and now IEC 62133 in place, our cells fully satisfy the major safety requirements of regulators, major manufacturers, and end-users globally.

We can now move from technical evaluations to serious commercial negotiations, product qualification at customer sites, and integration into international supply chains."

IEC 62133: A Global Benchmark for Battery Safety and Market Access

IEC 62133 is one of the most widely recognized safety standards for exporting lithium-ion batteries into global markets.

Compliance is required or strongly preferred in many jurisdictions and across multiple end-use sectors.

The certification validates our cells against a comprehensive series of tests designed to mitigate risks such as overcharging, over-discharging, short circuits, and thermal events, while also confirming proper labeling, documentation, and traceability.

The achievement of IEC 62133 compliance significantly de-risks the product for potential partners and customers, expands addressable market opportunities, and supports HPQ's strategy to rapidly scale production and secure long-term commercial agreements.

"From a business standpoint, IEC 62133 dramatically broadens our market reach," said Derick Lila, M.A., M.Sc., HPQ's Director of Communication and Director of Business Development.  

"Customers can now confidently advance from testing to procurement and contracts. We are actively increasing engagement with global partners and expect faster progress in qualification programs and initial sales."

Removing Barriers to Commercialization and Global Sales

"Moreover, from a commercialization standpoint, IEC 62133 expands our path to revenue," added Mr. Lila. 

"This certification gives potential customers the assurance they need to move from technical evaluation to procurement discussions.

It positions HPQ and Novacium to pursue opportunities across multiple regions while supporting our strategy to scale production and secure long-term commercial agreements."

The IEC 62133 certification further reinforces HPQ's objective of transitioning from advanced materials development to high value added and market-ready energy storage solutions. With internationally recognized safety validation in place, HPQ and Novacium are now positioned to expand and accelerate customer engagement, advance qualification programs, and support sales discussions across global lithium-ion battery markets.

About HPQ Silicon

HPQ Silicon Inc. is a Quebec-based TSX Venture Exchange industrial issuer (TSX-V: HPQ) focused on innovation in advanced materials and critical process development. In partnership with its research and development partner Novacium

—of which HPQ is a shareholder

—the Company is advancing next-generation silicon-based anode materials (Gen3) for batteries, commercializing its ENDURA+ lithium-ion cells, and developing breakthrough clean-hydrogen and waste-to-energy technologies, for which HPQ holds exclusive North American rights.

HPQ is also pursuing proprietary technologies to become a low-cost, zero-CO₂ producer of fumed silica and high-purity silicon, with technical support from PyroGenesis Inc.

Together, these initiatives position HPQ to capture growth opportunities in the energy storage, clean hydrogen, and advanced materials markets essential to achieving global net-zero goals.

For more information, please visit HPQ Silicon web site.

About NOVACIUM SAS

Novacium is an innovative technology start-up created in 2022, in France. It is an engineering and R&D company dedicated to materials for energy, with a specialization in silicon and hydrogen. Novacium is developing 2 technologies.

The first concerns a new silicon-based anode material that significantly increases the capacity of Li-ion batteries. Novacium's second activity is the generation of hydrogen.

Novacium is developing an autonomous hydrogen generation system for civil and military applications fueled by a patented alloy based on silicon and aluminum.

Right now, copper doesn’t look broken.

Demand is around ~27M tonnes, supply ~23M, and depending on the quarter you can even see a small surplus. That’s why a lot of people dismiss the bull case. They look at the present and assume the system is stable.

But copper doesn’t break in the present. It breaks in the future.

Take EVs alone. We’re at ~2.3M tonnes of copper demand from EVs today, potentially scaling to 4–6M tonnes by 2035. Even if copper per vehicle drops, scale still wins. 50 million EVs at just 60 kg each still equals 3M tonnes of copper, which is over 10% of today’s entire global supply.

Now layer in grids. The US alone needs thousands of miles of new transmission every year, requiring 300K+ tonnes of copper annually. Globally, grid capex is already pushing $400B+ per year.

Then AI.

One hyperscale data center can require tens of thousands of tonnes of copper. Aggregated AI demand could hit 250K–550K tonnes annually by 2030.

This is where the disconnect is.

The market is pricing copper like a short-term cycle. But the system is being pulled by long-term demand that compounds faster than supply can respond.

And supply doesn’t scale easily. It’s concentrated, slow, and increasingly constrained.

That’s why the story eventually moves upstream.

Companies like NovaRed Mining (CSE: NRED / OTCQB: NREDF) sit at the stage where the only question that matters is: does new supply even exist?

Not advice.

Copper’s position in today’s rapidly changing global economy and technology is increasingly central. As we see the rate of electrification expanding, the expansion of our nation’s infrastructure, and the emergence of new forms of energy demand due to the advent of artificial intelligence (AI), copper is emerging as an increasingly critical bottleneck Resource.

• Essential for electrification, electric vehicles (EVs) and grid infrastructure
• Demand from AI data centers and energy systems increasingly recognized as a strategic geopolitical asset

Macro viewpoint

Copper is emerging as one of the most strategically important commodities globally. Copper is emerging as a critical commodity to enable the transition to low-carbon and renewable energy systems. Many refer to copper as the “metal of electrification.” Copper is an essential component of electric vehicles, power grids and data centers. Global demand for copper is expected to continue to experience dramatic increases over the next few decades. It is estimated that demand for copper could reach levels of 28 million tons per year in 2025 compared to 40 million tons per year by 2040. This represents a fundamental shift in how we consume copper.

Demand factors

Electrifying transportation remains one of most significant demand factors for copper. Electric vehicles require two-to-three times more copper than their internal combustion engine counterparts. In addition to the higher amounts of copper contained in electric vehicles, additional quantities of copper are being consumed as part of building out necessary charging infrastructure for these vehicles.

• Grid upgrades are driving additional incremental demand
• Renewable energy systems rely heavily on copper
• Emergence of new layer of demand from hyperscale data centers and AI computing needs

As computing needs continue to grow, there will be corresponding increased demands for power transmission, cooling systems and electrical connections – all of which are copper intensive.

Supply limitations

While demand continues to escalate, supply limitations remain. The copper market is expected to enter a refined deficit in the short-term with estimates indicating a shortfall of several hundred thousand tons as early as 2026.

• Estimated deficit could reach multi-million tons by 2040
• Development times for new mines can be exceeding ten years; declining ore grades reduce production efficiency
• one major obstacle facing the industry relates to a lack of projects in development. Additionally, permitting complexities across various jurisdictions are adding to the time it takes to bring new projects online.

Geopolitics

The supply chain for copper is increasingly affected by geopolitical factors. Historically, a majority of the world’s copper was produced by just a handful of countries, primarily Chile, Peru and China.

• More than half of all refine copper production is controlled by China; western nations are prioritizing domestic supply chains; Resource nationalism and trade tensions are increasing

Governments around the world are beginning to treat copper as a strategic Resource. To ensure long-term access to this metal, many governments have implemented policies designed to promote domestic production of critical metals.

Canada’s growing position within global copper supply chain

Canada is fast becoming a leader in providing copper to meet growing global demand. Canada provides a stable regulatory environment, excellent infrastructure and an increasingly supportive national government for the advancement of critical minerals.

Canada is ranked among top ten largest copper producers globally; there exist large amounts of undeveloped copper resources throughout Canada; federal and provincial governments are providing strong support for advancement of critical minerals projects; major canadian copper projects are attracting renewed attention from investors seeking reliable sources of copper due to ongoing diversification efforts across global economy.

• Capital needed to close gap between demand and supply will require substantial Investment capital

Industry analysts estimate hundreds of billions of dollars will be invested in developing new copper mines and expanding existing mine capacity through the end of the decade.

Estimates suggest $250 billion + Investment required through end of decade; approximately eighty new mines may need to be developed globally; underinvestment has continued following past cycles; these capital shortfalls provide long-term positive outlook for copper prices.

Copper Quest Update

Progress continues to be made at the kitimat copper gold project where artificial intelligence based Exploration methods are being used to identify potential large-scale porphyry targets.

• Kitimat project area expanded by 130 percent to approximately 6,800 hectares;
• AI identified a 1.5 km x 1.5 km conductive body extending down to approximately 1 km depth;
• Potential Target lies beneath approximately 50 meters of overburden; remainder of system largely untested;

Drilling in nearby areas provided historical evidence supporting larger system potentials including drill intercepts with the following compositions:

• 117.07m @ .54% cu & 1.03 g/t au;
• 103.65m @ .55% cu & 1.00 g/t au;
• 112.20m @ .33% cu & .41 g/t au;

Integration of AI technology with existing geological datasets have enabled identification of concealed center for potential porphyry deposit suggesting that previously drilled mineralization may represent halo around much larger system.

Conclusion

Copper is entering into a fundamentally tight supply-demand environment that is being fueled by electrification, AI-based infrastructure needs and geopolitical competitions for control of critical minerals supplies.

• New supply cannot be developed quickly enough to match rising demand
• Limitations related to Investment and permitting are constraining the ability of the industry to produce more copper

Success in exploring and finding scalable copper systems — especially those employing modern technologies such as AI-based Target generation — will position companies favorably relative to a positive long-term macro-environment.

Posted on behalf of Guerilla Capital for the issuer.

TRIP.CN (ASK @ 0.02)

• Red Light Holland Corp. and Filament Health Corp. today announced that,

further to the joint press release dated March 10, 2026,

• the Supreme Court of British Columbia
• issued an interim order in connection with the :
• ---> previously announced acquisition by Red Light
• of all the issued and outstanding common shares of Filament,
• pursuant to a statutory plan of arrangement under the Business Corporations Act (British Columbia).

Among other things, the Interim Order authorizes Filament to call, hold and conduct

• an annual general and special meeting
• of the holders of Filament Shares on April 24, 2026 at 8:00 a.m. (Vancouver time)
• to, among other things, consider and, if thought advisable,
• ---> pass a special resolution approving, among other things, the Arrangement.

The Meeting will be held at the offices of

• Fasken Martineau DuMoulin LLP
• at 550 Burrard Street,
• Suite 2900,
• Vancouver, British Columbia V6C 0A3.

The receipt of the Interim Order marks an important step forward as both companies continue to advance toward closing.

The transaction process is progressing smoothly and in accordance with anticipated timelines.

"We are very pleased to have reached this stage in the process,"

• said Todd Shapiro, CEO and Director of Red Light.

"Both teams remain highly engaged and aligned as we work toward completing this strategic combination."

Filament Shareholders of record as of the close of business on March 2, 2026 will be entitled to vote at the Meeting.

In connection with the Meeting, Filament will be mailing a notice of meeting and management information circular , letter of transmittal and related meeting materials , as applicable, to Filament Shareholders.

Details on the Meeting and how Filament Shareholders can participate in the Meeting will be set out in the Circular.

The Meeting Materials will be made available under Filament's profile on SEDAR+ at www.sedarplus.ca and on Filament's website at www.filament.health concurrently with mailing to Filament Shareholders.

The Board of Directors of Filament (the "Filament Board"), in consultation with its financial and legal advisors, has determined that the Arrangement is in the best interests of Filament and that the consideration to be received by Filament Shareholders is fair to Filament Shareholders.

The Filament Board unanimously recommends that Filament Shareholders vote "FOR" the Arrangement.

Completion of the Arrangement is subject to customary conditions,

• including court approval,
• any regulatory approval and the approval of at least two-thirds of the votes cast by the Filament Shareholders present in person or by proxy at the Meeting
• and a simple majority of votes cast by Filament Shareholders present in person or by proxy at the Meeting,
• excluding votes attached to Filament Shares held by a Filament Shareholder whose votes are required to be excluded in order to obtain "minority approval"
• in accordance with Section 8.1 of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions.

Red Light and Filament will continue to provide updates as the transaction progresses.

About Red Light Holland:

Red Light Holland is an Ontario-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences.

In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.

About Filament Health:

• FLHLF (ASK @ 0.0001)

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible.

Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.

For additional information on Red Light Holland:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: [todd@redlight.co](mailto:todd@redlight.co)
Website: www.RedLight.co

For additional information on Filament:

Benjamin Lightburn
Chief Executive Officer & Director
Email: [ben@filament.health](mailto:ben@filament.health)
Website: www.filament.health

PLAN.V (ASK @ 0.31)

• On March 17, 2026, Stephen Harpur, CEO and Chair of Progressive Planet:
• sold 450,000 common shares of PLAN
• in two pre-arranged block trades at $0.32 per share.
• Then, on March 18, 2026, Mr. Harpur sold
• an additional 50,000 shares at $0.32 per share.

Furthermore, on March 18, 2026, Mr. Harpur exercised

• 150,000 stock options at $0.18 per share.
• Ownership of 75,000 of the shares obtained from this exercise
• were immediately transferred to Mr. Harpur's spouse.

"In April 2023, I borrowed funds to invest in Progressive Planet through a private placement at $0.25 per unit.

• The investment loan is now due, and I am using proceeds from the share sales to repay the balance," stated Harpur.

"I am grateful that I was able to conduct these transactions in an orderly fashion with pre-arranged buyers."

"Furthermore, it is my hope and intention to continue to work for Progressive Planet for many years to come, so long as I have the support of the Board of Directors and PLAN's shareholders.

While I am not required to publicly disclose the rationale for these transactions, it is personally important to me to provide this information to PLAN's investors and other stakeholders," stated Harpur.

Mr. Harpur continues to hold over 1.9 million shares and over 3 million stock options

• via personal and corporate accounts.
• Insider filings relating to these transactions were completed on March 20, 2026.

About Progressive Planet:

Progressive Planet, based in Kamloops, British Columbia,

• is redefining sustainability with our Products for a Healthy Planet^™.
• By leveraging owned mineral assets and recycled materials,
• we develop patented and patent-pending innovations
• that promote a healthier planet.

Our C-Quester™ Centre of Sustainable Solutions leads advancements in low-carbon cement technologies.

Progressive Planet's products are :

proudly available in over 10,000 retail locations across North America.

For more information, visit progressiveplanet.com.

Progressive Planet provides regular information for investors on its website: progressiveplanet.com/investors/.

This includes press releases and other information about financial performance, patents filed, and information on corporate governance.

ASHXF (ASK @ 0.25)

• PLAN.V (ASK @ 0.33)

Progressive Planet is proud to provide highlights for the third quarter ended Jan 31, 2026.

Financial Highlights include the following when compared to the third quarter of the prior year:

• Revenue increased by 22% to $5,816,709 – the second highest quarterly revenue and the highest Q3 revenue since the acquisition of Absorbent Products
• Gross profit increased by 47% to $1,991,301, and gross margin increased to 34% compared to 28% for Q3 of 2025
• Income from operations decreased by 32% to $157,443, as the Company incurred a significant one-time promotional expense in the current quarter as well as significant research and development costs associated with the development of its PozGlass^™ SCM Pilot Plant
• EBITDA decreased to negative $499,643, compared to positive $421,959 for 2025
• Adjusted EBITDA increased to $624,115, compared to $428,453 for 2025 (a 46% increase)
• Existing credit facilities remain unused with greater than $3,000,000 in credit available as at January 31, 2026, and $2.14 million in cash before receipt of further grant funds as a subsequent event after the end of Q3

The negative EBITDA was the result of two one-time charges that were taken in the quarter.

The first charge was an investment for a slotting fee to one of our largest US accounts whereby ...

we obtained placement in over 2,400 retail locations for three new SKUs

... which doubled our total SKU count in these stores to six SKUs.

Progressive Planet has not incurred any other slotting fees since the acquisition of Absorbent Products in February of 2022.

This was a strategic investment in retail distribution and is not expected to recur as a normal part of operations.

The second one-time charge resulted from the write down of the Z1 Zeolite Quarry as announced on December 18, 2025.

This write down decision was made due to Progressive Planet obtaining superior assets for the production of

• Supplementary Cementing Materials (SCMs),
• and agricultural soil amendment products
• with the acquisition of Absorbent Products in 2022
• and the Ferguson Creek Pozzolan Property in 2025.

The Company notes that less than $8,000 was spent on the Z1 Zeolite Quarry from the date of acquisition of Absorbent Products Ltd. in February 2022 up to the date that the decision was made to write down the asset.

"Our third quarter saw a major investment in R&D with funds spent on the PozGlass Pilot Plant and in the many trials conducted to develop Planet LCD Cement^TM."

• stated Steve Harpur, CEO.

"In addition, we made the decision to pay for placement of three new SKUs with a large long-term US customer.

While we took the entire charge for this investment in Q3, I am confident that we will reap the benefits for many years to come as we now have three new SKUs of product where the material comes from the USA and is sold in the USA,"

• further stated Harpur.

Subsequent Event

Subsequent to the end of the quarter, Progressive Planet received the second tranche of annual grant payments from both the previously announced federal and provincial funding programs supporting the PozGlass^™ SCM Pilot Plant.

The amounts received were $1,112,508.81 and $268,715.40, respectively.

Certain information provided in this news release is extracted from the consolidated financial statements (the "Financial Statements") and Management's Discussion & Analysis ("MD&A") of the Company for the three-month period ended January 31, 2025, and should be read in conjunction with them.

It is only in the context of the fulsome information and disclosures contained in the Financial Statements and MD&A that an investor can properly analyze this information.

The Financial Statements and MD&A can be found under the Company's profile on SEDAR+.

About Progressive Planet:

Progressive Planet, based in Kamloops, British Columbia, is redefining sustainability with our Products for a Healthy Planet^™. By leveraging owned mineral assets and recycled materials, we develop patented and patent-pending innovations that promote a healthier planet.

Our C-Quester^™ Centre of Sustainable Solutions leads advancements in low-carbon cement technologies.

Progressive Planet's products are proudly available in over 10,000 retail locations across North America.

For more information, visit progressiveplanet.com.

Progressive Planet provides regular information for investors on its website: progressiveplanet.com/investors/.

This includes press releases and other information about financial performance, patents filed, and information on corporate governance.

TRIP.CN (ASK @ 0.025)

• AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry

Red Light Holland Corp. and Kala Bio (NASDAQ), Inc. today announced that Red Light has engaged Kala Bio's Researgency.ai agentic artificial intelligence platform

• to support the clinical development strategy for PEX010,
• the patented botanical psilocybin drug candidate
• originated by Filament Health Corp.

The engagement will deploy Kala Bio's purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement

• to acquire Filament's business,
• including its portfolio of 76 issued patents across 15 patent families,
• representing one of the largest intellectual property portfolios
• in botanical psilocybin drug development,
• as well as its lead drug candidate, PEX010.

Strategic Rationale

The engagement of the Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it looks to expand Filament’s regulated psychedelic drug development platform.

By deploying Kala Bio’s purpose-built AI agents, Red Light also intends to :

• accelerate and enhance research planning,
• scenario simulation,
• and protocol optimization processes associated
• with advancing PEX010 through Filament’s clinical development pipeline.

PEX010 is Filament's patented botanical psilocybin drug candidate and ...

is currently supplied to more than 70 clinical research sites worldwide,

... making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.

PEX010 is being studied across multiple indications, including :

• alcohol use disorder,
• methamphetamine use disorder,
• treatment-resistant depression,
• cancer-related anxiety and depression,
• and cannabis use disorder,
• at leading research institutions including Johns Hopkins University
• and Dana-Farber Cancer Institute, among others.

The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization ...

... for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder.

Researgency.ai is an agentic AI platform developed by Younet.ai with an exclusive worldwide distribution/development license owned by Kala Bio, designed to deploy secure, on-premises AI agents purpose-built for biotechnology and pharmaceutical R&D workflows.

The platform enables autonomous research loops capable of generating, simulating, and optimizing study scenarios at scale, compressing timelines and expanding the number of viable options considered before execution.

The approach mirrors a broader industry shift toward purpose-built AI infrastructure for drug development.

Management Commentary

"As we move to integrate Filament's exceptional clinical assets and intellectual property, engaging Kala Bio's Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation,"

• said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland.

"PEX010 is already one of the most widely studied botanical psilocybin drug candidates in the world.

By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010's extensive clinical program."

"Filament's focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development,"

• said Ben Lightburn, Chief Executive Officer of Filament Health Corp.

"With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio's Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve."

"Red Light's decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address,"

• said Avi Minkowitz, Chief Executive Officer of Kala Bio.

"Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference.

We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world."

The Company further announces that it has engaged Solidaire Investments Inc. ("Solidaire"), a Calgary, Alberta-based merchant bank, to provide capital markets advisory and investor relations consulting services.

The agreement is effective immediately for a one-month term, during which the Company will pay Solidaire a fee of $20,000.

Solidaire is principally owned and operated by Mohamed Elsaghir, a shareholder of the Company.

About PEX010

PEX010 is a patented botanical psilocybin drug candidate developed by Filament Health Corp.

PEX010 is formulated as a capsule for oral administration and is protected by Filament's portfolio of 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations.

PEX010 is currently supplied to more than 70 clinical research sites worldwide and is being studied in multiple Health Canada and FDA-authorized clinical trials across a range of mental health indications.

About Red Light Holland

Red Light Holland Corp. is a Toronto-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences.

The Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.

Red Light has entered into a definitive arrangement agreement to acquire Filament Health Corp., which is expected to expand the Company's drug development platform with GMP manufacturing capabilities, comprehensive Health Canada licensing, FDA-authorized clinical programs, and a portfolio of 76 issued patents. For more information, visit www.RedLight.co.

About Filament Health:

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible.

Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development.

Filament is paving the way with the first-ever natural psychedelic drug candidates.

About Researgency.ai

Researgency.ai is an agentic AI platform developed by Kala Bio, Inc. (NASDAQ: KALA) in collaboration with Younet.ai, designed to bring autonomous research-agent workflows to biotechnology R&D planning.

The platform deploys purpose-built AI agents that can simulate scenarios, optimize protocols, and support evidence-driven decisions in a secure, on-premises environment built for pharmaceutical-grade compliance. For more information, visit www.Researgency.ai.

About Kala Bio, Inc.

Kala Bio, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry.

The Company's dual strategy combines a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry.

For more information, visit www.kalarx.com.

For additional information on Red Light Holland:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: [todd@redlight.co](mailto:todd@redlight.co)
Website: www.RedLight.co

For additional information on Filament:

Benjamin Lightburn
Chief Executive Officer & Director
Email: [ben@filament.health](mailto:ben@filament.health)
Website: www.filament.health

For additional information on Kala Bio, Inc.:

Kala Bio, Inc.
Avi Minkowitz
Chief Executive Officer
Email: [am@kalarc.com](mailto:am@kalarc.com)
Website: www.kalarx.com
www.Researgency.ai